Official Protocol Title:
NCT number: [STUDY_ID_REMOVED]
Document Date:           16-Mar-2020
A Randomized, Double-Blind, Placebo-
Controlled Study of the Safety and 
Pharmacokinetics of MK-1942 Administered to 
Alzheimer’s Disease Patients Receiving 
Donepezil Treatment

PRODUCT: MK-1942  1
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD) .
Protocol Title: A Randomized, Double -Blind, Placebo -Controlled Study  of the Safet y and 
Pharmacokinetics of MK -1942 Administered to Alzheimer’s Disease Patients Receiving 
Donepezil Treatment.
Protocol Number: 005-01
Compound Nu mber: MK-1942
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889 -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND 139557
Approval Date:   16 March 2020
087PVJ
PRODUCT: MK-1942  2
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
Title:Date
087PVJ
PRODUCT: MK-1942  3
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 01 16-MAR -2020 Correction of NI MP designation of donepezil was required to ensure proper 
safet y reporting to regulatory  agency . Other editorial changes were 
implemented and information on the ongoing P004 was updated.
Original Protocol 10-JAN-2020 Not Applicable
087PVJ
PRODUCT: MK-1942  4
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: MK-1942- 005-01
Overall Rationale for the Amendments:
Correction of NI MP designation of donepezil was required to ensure proper safet y reporting to regulatory  agency . Other editorial 
changes were implemented and information on the ongoing P004 was updated.
Summary of Changes Table:
Section # and Name Description of Change  Brief Rationale  
Section 1.3 Schedule of 
ActivitiesRemove 24hr timepoint from footnote “m” 24hr timepoint overlapped with the pre -dose measurement 
on the following day. Removing this timepoint eliminated 
the redundant timepoint.
Section 2.2.3.2 MK -1942-
004Added dosing and safet y data up to Panel 
B in P004. Ensure protocol has the most recent information on the 
safet y and tolerability  of MK -1942 in study  P004 as of the 
time of this amendment.
Section 5.2 Exclusion 
CriteriaExclusion #10 – removed text below
“Is unable to refrain from or anticipates the 
use of an y medication, including 
prescription and non -prescription drugs or 
herbal remedies (see Section 6.5, item 8 for 
specific examples), beginning 
approximately  2weeks (or 5 half -lives) 
prior to administration of the initial dose of 
study  drug, throughout the study  (including 
intervals between treatment periods), until 
the post -study  visit. There may  be certain 
medications that are permitted (see Section 
6.5).”PN005 is being conducted in an elderl y population likely  to 
be taking prescription medications for chronic conditions.  
The highlighted section cause sconfus ion around those 
medications that are permitted in the study . In order to 
ensure clarity  around which concomitant medications are 
permitted in candidates for enrollment and under what 
conditions, this section was removed.  The remaining text 
in Exclusion criteria 10 states “All medications being taken 
by candidates for enrollment in the study  should be 
reviewed b y the PI and the Sponsor to determine their 
propensity  for altering MK- 1942 exposure, or for MK -1942 
to interfere with the metabolism of the medication. 
Medications prescribed for the candidate that are stably  
treating a condition should not be int errupted.  
087PVJ
PRODUCT: MK-1942  5
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Section # and Name Description of Change  Brief Rationale  
Section 6.1 Study  
Interventions 
Administered, Table 7Changed donepezil designation from 
Investigational Medicinal Product (IMP) to 
Non-Investigational Medicinal Product 
(NIMP) .Donepezil was incorrectly  labeled as IMP. Correction was 
needed to ensure proper safet y reporting. 
Section 6.5 Concomitant 
Therap yRemov edfelbamate, topiramate, 
probenecid, lamotrigine and riluzole from 
the list of prohibited concomitant 
medicationsNew pre-clinical data suggest that the potential for a DDIs 
with these drugs is low . 
Section 8.10.5 Critical 
Procedures Based on 
Study  Objectives: Timing 
of ProcedurePredose safety  standard safet y evaluations: 
Added that windows are prior to dosing. 
Changed ECG window from 3hrs to 1 hr 
prior to dosing. Editorial change to ensure clarit y of interpretation. 
ECG window narrowed to ensure it is a sclose to dosing as 
possible. 
Sections 4.2.1.3 Future 
Biomedical Research, 
8.1.1.2 Consent an d 
Collection of Specimens 
for Future Biomedical 
Research and Appendix 
10.6 Collection and 
Management of 
Specimens for Future 
Biomedical ResearchRemoval of the word “substudy ” New template requirement
087PVJ
PRODUCT: MK-1942  6
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 13
1.1 Synopsis ................................................................................................................. 13
1.2 Schema .................................................................................................................. 16
1.3 Schedule of Activities ........................................................................................... 18
2 INTRODUCTION .......................................................................................................... 22
2.1 Study Rationale ....................................................................................................22
2.2 Background .......................................................................................................... 23
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 23
2.2.2 Preclinical and Clinical Studies ...................................................................23
2.2.3 Ongoing Clinical Studies ............................................................................. 23
2.2.3.1 MK-1942- 002: A Double -Blind, Placebo -Controlled, Multiple 
Ascending Dose Stud y of the Safet y, Tolerability and 
Pharmacokinetics of MK -1942 in Health y Participants .................... 23
2.2.3.2 MK-1942- 004: A Randomized, Double Blind, Placebo -
Controlled I nvestigation of the Safet y, Tolerability and 
Pharmacokinetics of Multiple -Dose Regimens of MK- 1942 in 
Health yElderl y Participants .............................................................. 37
2.2.4 Information on Other Study -related Therap y.............................................. 38
2.3 Benefit/Risk Assessment ...................................................................................... 39
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 39
4 STUDY DESIGN ............................................................................................................ 40
4.1 Overall Design ......................................................................................................40
4.2 Scientific Rationale for Study Design ................................................................ .41
4.2.1 Rationale for Endpoints ............................................................................... 42
4.2.1.1 Safety  Endpoints ................................................................................ 42
Pharmacokinetic Endpoints ................................................................................... 43
4.2.1.2 Planned Exploratory  Biomarker Research ......................................... 44
4.2.1.2.1 Planned Genetic Anal ysis........................................................ 44
4.2.1.3 Future Biomedical Research .............................................................. 44
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 45
4.2.3 Rationale for Suicidal Ideation and Behavior Monitoring ........................... 45
4.3 Justification for Dose ........................................................................................... 45
4.3.1 Starting Dose for This Study ........................................................................45
4.3.2 Maximum Dose/Exposure for This Study ................................................... 46
087PVJ
PRODUCT: MK-1942  7
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
4.3.3 Rationale for Dose Interval and Study Design ............................................ 47
4.4 Beginn ing and End of Study Definition ............................................................. 48
4.4.1 Clinical Criteria for Early Study Termination ............................................. 48
5 STUDY POPULATION ................................................................................................ 49
5.1 Inclusion Criteria ................................................................................................ .49
5.2 Exclusion Criteria ................................................................................................ 51
5.3 Lifestyle Considerations ...................................................................................... 54
5.3.1 Meals and Dietary Restrictions ....................................................................54
5.3.1.1 Diet Restrictions................................................................................. 54
5.3.1.2 Fruit Juice Restrictions ......................................................................54
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions .............................................. 54
5.3.2.1 Caffeine Restrictions .......................................................................... 54
5.3.2.2 Alcohol Restrictions ........................................................................... 55
5.3.2.3 Tobacco Restrictions .......................................................................... 55
5.3.3 Activity  Restrictions .................................................................................... 55
5.4 Screen Failures .....................................................................................................55
5.5 Participant Replacement Strategy ......................................................................55
6 STUDY INTERVENTION ............................................................................................ 56
6.1 Study Intervention(s) Administered ...................................................................56
6.2 Preparation/Handling/Storage/Accountability ................................................. 58
6.2.1 Dose Preparation .......................................................................................... 58
6.2.2 Handling, Storage, and Accountability ........................................................ 58
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 59
6.3.1 Intervention Assignment.............................................................................. 59
6.3.2 Stratification ................................................................................................ .59
6.3.3 Blinding........................................................................................................59
6.4 Study Intervention Compliance .......................................................................... 59
6.5 Concomitant Therapy .......................................................................................... 59
6.5.1 Rescue Medications and Supportive Care ................................................... 61
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 61
6.6.1 Stopping Rules ............................................................................................. 61
6.6.2 Dizziness/Nausea Stopping Criteria ............................................................ 61
6.7 Intervention After the End of the Study ............................................................ 63
6.8 Clinical Supplies Disclosure ................................................................................ 63
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL ............................................................................................................ 63
7.1 Discontinuation of Study Intervention ............................................................... 63
7.2 Participant Withdrawal From the Study ........................................................... 64
087PVJ
PRODUCT: MK-1942  8
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
7.3 Lost to Follow -up................................................................................................ .65
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 65
8.1 Administrative and General Procedures ........................................................... 66
8.1.1 Informed Consent ......................................................................................... 66
8.1.1.1 General Informed Consent ................................................................ .66
8.1.1.2 Consent and Collection of Specimens for Future Biomedica l 
Research ............................................................................................. 67
8.1.2 Inclusion/Exclusion Criteria ........................................................................67
8.1.3 Participant Id entification Card .....................................................................67
8.1.4 Medical History ........................................................................................... 68
8.1.5 Prior and Concomitant Medications Review ............................................... 68
8.1.5.1 Prior Medications ............................................................................... 68
8.1.5.2 Concomitant Me dications ..................................................................68
8.1.6 Assignment of Screening Number ............................................................... 68
8.1.7 Assignment of Treatment/Randomization Number .....................................68
8.1.8 Study  Intervention Administration .............................................................. 69
8.1.8.1 Timing of Dose Administration ......................................................... 69
8.1.9 Discontinuation and Withdrawal ................................................................ .69
8.1.9.1 Withdrawal From Future Biomedical Research ................................ 70
8.1.10 Participant Blinding/Unblinding ..................................................................70
8.1.11 Domiciling ...................................................................................................71
8.1.12 Calibration of Equipment ............................................................................. 71
8.2 Efficacy/Immunogenicity Assessments .............................................................. 71
8.3 Safety Assessments ............................................................................................... 71
8.3.1 Physical Examinations ................................................................................. 72
8.3.2 Vital Signs....................................................................................................72
8.3.2.1 Resting Vital Signs ............................................................................ 72
8.3.2.2 Orthostatic Vital Signs.......................................................................73
8.3.3 Electrocardiograms ...................................................................................... 73
8.3.4 Neurological Exams ..................................................................................... 74
8.3.5 Mini -Mental State Examination (MMSE- 2)................................................ 74
8.3.6 WAI S-R Digit Sy mbol Substitution Test (DSST) .......................................74
8.3.7 Clinical Safety  Laboratory  Assessments ..................................................... 74
8.3.8 Suicidal I deation and Behavior Monitoring ................................................. 75
8.3.8.1 Clinical Assessments for Suicidal I deation and Behavior 
Monitoring ......................................................................................... 75
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 75
087PVJ
PRODUCT: MK-1942  9
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 76
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......78
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...78
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 78
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 78
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ 78
8.4.7 Events of Clinical I nterest ............................................................................ 78
8.5 Treatment of Overdose ........................................................................................ 79
8.6 Pharmacokinetics................................................................................................ .79
8.6.1 Blood Collection for Plasma MK- 1942 ....................................................... 79
8.7 Pharmacodynamics .............................................................................................. 80
8.8 Biomarkers ........................................................................................................... 80
8.8.1 Planned Genetic Anal ysis Sample Collection .............................................. 80
8.9 Future Biomedical Research Sample Collection ............................................... 80
8.10 Visit Requirements ............................................................................................... 80
8.10.1 Screening......................................................................................................80
8.10.2 Treatment Period Visit................................................................................. 81
8.10.3 Discontinued Participants Continuing to be Monitored in the Study .......... 81
8.10.4 Poststudy ......................................................................................................81
8.10.5 Critical Procedures Based on Study  Objectives: Timing of Procedure .......81
8.10.6 Study  Design/Dosi ng/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 82
9 STATISTICAL ANALYSIS PLAN ............................................................................. 83
9.1 Statistical Analysis Plan Summary.....................................................................84
9.2 Responsibility for Analyses ................................................................................. 85
9.3 Hypotheses/Estimation ........................................................................................ 86
9.4 Analysis Endpoints ............................................................................................... 86
9.5 Analysis Populations ............................................................................................ 86
9.6 Statistical Methods ............................................................................................... 87
9.6.1 Safety ........................................................................................................... 87
9.6.2 Pharmacokinetics ......................................................................................... 87
9.6.3 General ......................................................................................................... 89
9.7 Interim Analyses ..................................................................................................89
9.8 Multiplicity ........................................................................................................... 89
9.9 Sample Size and Power Calculations ................................................................ .90
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................91
087PVJ
PRODUCT: MK-1942  10
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........91
10.1.1 Code of Conduct for Clinical Trials ............................................................. 91
10.1.2 Financial Disclosure ..................................................................................... 93
10.1.3 Data Protection ............................................................................................. 93
10.1.3.1 Confidentiality  of Data ......................................................................94
10.1.3.2 Confidentiality  of Participant Records ............................................... 94
10.1.3.3 Confidentiality  of IRB/IEC I nformation ............................................ 94
10.1.4 Publication Policy ........................................................................................ 94
10.1.5 Compliance with Study  Registration and Results Posting Requiremen ts...95
10.1.6 Compliance with Law, Audit, and Debarment ............................................ 95
10.1.7 Data Qu ality Assurance ............................................................................... 96
10.1.8 Source Documents ....................................................................................... 97
10.1.9 Study  and Site Closure ................................................................................. 97
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 98
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 99
10.3.1 Definition of AE .......................................................................................... 99
10.3.2 Definition of SAE ...................................................................................... 100
10.3.3 Additional Events Reported .......................................................................101
10.3.4 Recording AE and SAE ............................................................................. 101
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ......................................................................................................105
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation ..................................106
10.5 Appendix 5: Contraceptive Guidance .............................................................. 107
10.5.1 Definitions ..................................................................................................1 07
10.5.2 Contraception Requirements ......................................................................108
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 109
10.7 Appendix 7: Country -specific Requirements .................................................. 114
10.8 Appendix 8: Approximate Blood Volume Table ............................................. 115
10.9 Appendix 9: 12- Lead Electrocardiogram Abnormality Criteria .................. 116
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values ...118
10.11 Appendix 11: The General and Targeted Neurological Exams ..................... 119
10.12 Appendix 12: Additional Information to be Collected from Subjects Who 
Report Suicidal Ideation and/or Behavior ....................................................... 125
10.13 Appendix 13: Abbreviations ............................................................................. 126
11 REFERENCES............................................................................................................. 128
087PVJ
PRODUCT: MK-1942  11
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
LIST OF TABLES
Table 1 Proposed Dosing Regimens of MK -1942 and Donepezil for the Study ........... 16
Table 2 Summary  of the Pharmacokinetic Parameters of MK -1942 Following 
Administration of Multiple Ascending Oral Doses to Healthy  Adult 
Subjects ............................................................................................................. 25
Table 3 Subjects Reporting Adverse Events (Incidence > 0% in One or More 
Treatment Groups) ............................................................................................ 30
Table 4 Calculated  on the Last Day  of Each Dose 
Level Following Treatment of Health y Adult Participants with Oral Doses 
of MK -1942 in Panel B ..................................................................................... 37
Table 5 Proposed Dosing Regimens for MK- 1942- 004-001......................................... 38
Table 6 Projected Sy stemic Exposures and Receptor Occupancies Achieved at 
Steady  State with the Proposed Dose Levels. ................................................... 46
Table 7 Study  Interventions ............................................................................................ 57
Table 8 Sample Allocation Schedule ............................................................................. 59
Table 9 Reporting Time Periods and Time Frames for Adverse Eve nts and Other 
Reportable Safet y Events .................................................................................. 77
Table 10 Pharmacokinetic Sample (Blood) Collection Windows ....................................82
Table 11 Operating Characteristics for a One AE Incidence Rate ...................................90
Table 12 Protocol -required Safet y Laboratory  Assessments ........................................... 98
CCI
087PVJ
PRODUCT: MK-1942  12
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
LIST OF FIGURES
Figure 1 Timing of Monitoring and I nterventions ........................................................... 17
Figure 2 Mean (SD) Plasma Concentration Time Profiles for MK -1942 Following 
Administration of Multiple Oral Doses to Health y Adult Subjects in Panels 
E and F (red) from Study MK -1942- 002. (Top ; Linear Scale, Bottom; Log -
linear Scale) .......................................................................................................28
Figure 3 Amelioration of Scopolamine -Induced Cognitive Impairment b y an 
...................................................................................................46
CCI
087PVJ
PRODUCT: MK-1942  13
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Randomized, Double -Blind, Placebo -Controlled Study  of the Safet y and 
Pharmacokinetics of MK -1942 Administered to Alzheimer’s Disease Patients Receiving 
Donepezil Treatment.
Short Title: MK-1942/Donepezil I nteraction sin AD Patients
Acronym: DDI
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
The study  population consists of A lzheimer Disease (AD) patients with mild to moderate 
cognitive impairment, 50-85 years of age. 
Primary  Objectives Primary  Endpoints
-Evaluate the safet y and tolerability  of 
treatment (MK -1942 co -administered with 
donepezil) in AD patients with mild -to-
moderate cognitive impairment. -Safet y measures (VS, ECGs, clinical 
chemistry , hematology , urinaly sis, targeted 
neurological exams, Columbia suicide 
severit y rating scale) and Adverse Event 
reports
Secondary  Objectives Secondary  Endpoints
-Evaluate the effects of donepezil on the PK 
of MK -1942 in AD patients
Hypothesis
-The plasma Cmax of MK -1942 determined 
on the last day  of a titrated treatment regimen 
(Day  21 [28]) when co -administered with 
donepezil to AD patients is similar to the 
Cmax obtained fo llowing administration of 
MK-1942 to HEV from MK -1942- 004, Panel 
C. That is, the true GMR (MK -1942 + 
donepezil in AD / MK -1942 in HEV) is 
contained within the interval (0.5, 2.0).
-Evaluate the effects of MK -1942 on the PK 
of donepezil in AD patients. 
Estimation: 
-Estimate the GMRs of plasma PK 
parameters (AUC0 -24, Cmax) for donepezil 
before and during administration of donepezil 
+ MK- 1942 to AD patients.-Cmax, AUC0- 12, AUC0 -24, Ctrough, 
Tmax, apparent terminal t1/2, CL ss/F, and 
Vzss/F of MK- 1942
-AUC0 -24, Cmax, Ctrough, Tmax for 
donepezil
087PVJ
PRODUCT: MK-1942  14
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Overall Desig n:
Study  Phase Phase 1
Primary  Purpose Treatment
Indication Alzheimer Disease
Population AD patients with mild -to-moderate cognitive impairment
Study  Type Interventional
Intervention Model Single Group
This is a multi- sitestudy .
Type of Control Placebo
Study  Blinding Double -blind
Blinding Roles Participants or Subjects
Investigator
Sponsor
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately 24weeks from the time the first participant 
signs the informed consent until the last participant’s last 
study -related telephone call or visit.
Number of Participant s:
Approximately  24participants will be allocated/randomized .
087PVJ
PRODUCT: MK-1942  15
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Intervention Groups and Du ration :
Intervention 
Group s Intervention 
Group Name DrugDose 
StrengthDose 
FrequencyRoute of 
Admin is--
trationRegimen/
Treat ment Period Use
AD Patients MK-1942 1-mg, 
5-mg, 
10-mgBID PO 8-mg BID x 7D; 
15-mg BID x 7D; 
30-mg BID x 7 D;
50-mg BID x 7D 
(provisional)Ex-
perimen -
tal
MK-1942 
PlaceboN/A BID PO BID x 21 (28) D Ex-
perimen -
tal
Abbreviations D, day; N/A, not applicable
Total 
Number1 Arm 
Duration of 
ParticipationEach individual will participate in the study  for approximately  11weeks from 
the time the ysign the Informed Consent Form through the final contact. After 
a screening phase of 5 weeks, each participant will receiv ethe assigned 
intervention for approximately 4 weeks. After the end of treatment ,each 
participant will be follow ed for an additional 2 weeks .
Study Governance Committees:
Steering Committee No
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Insert Other Oversight Committee No
There are no governance committees in this study .
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 13.
087PVJ
PRODUCT: MK-1942  16
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
1.2 Schema
The study  design is depicted in Table 1 .
Table 1 Proposed Dosing Regimens of MK -1942 and Donepezil for the Study  
TreatmentaStudy Week
1 2 3 (4)
Donepezil 
(personal 
prescription)≥10-mg, ≤15-mgQD x 28 D
MK-1942/ 
Placebo8-mg BID x 7D 15-mg BID x 7D 30-mg BID x 7Db≤50-mg BID x 7Dc
(Provisional)
Abbreviations: D, day
a:There will be 18participants randomized to receive MK -1942 and 6 participants to receive matching 
placebo. Assignment of participants to their treatments will be determined according to a computer -generated 
allocation schedule. MK-1942/matching placebo w ill be administered as a DFC formulation. Refer to Section 
6.6 (Dose Modification) for the safety, tolerabili ty and PK data that will be reviewed prior to dose escalation.
b:The doses for Dose Level s 3 and 4 will be based on the safety and tolerability of the highest dose s
administered in MK-1942- 004(Section 2.2.3). The dose of MK -1942 will not exceed 50-mgBID.
c:The proposed fourth dose level is provisional, pending the results of all available safety ,tolerability and 
PK data from the previous dose- levels .  
087PVJ
PRODUCT: MK-1942  17
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
CRU = Clinical research unit, Pbo = Placebo
Figure 1Timing of Monitoring and I nterventions 
087PVJ
PRODUCT: MK-1942  18
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
1.3 Schedule of Activities
Study Period Screening Intervention (Days)aPost-Treatment 
Safety 
MonitoringPost-
study
Scheduled DayUp 
to 
day    
-35-
2-
11 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 42
Administrative Procedures
Informed Consent X
Informed Consent 
for Future 
Biomedical 
ResearchX
Participant 
Identification CardX
Screening Procedures/Reviews
Medical History X
Prior/Concomitant 
Medication ReviewX --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- X
Height (BMI) X
Weight X X X
Full physical 
examinationb X X X X
Full Neurological 
ExaminationX X
HIV, hepatitis B 
and C screenX
Follicle Stimulating 
Hormone (FSH) 
(females only)X
Urine Drug ScreencX X
CYP2C19 
GenotypingX
MMSE -2dX X X
DSSTeX X X X X
C-SSRS 
Baseline/ScreeningX
087PVJ
PRODUCT: MK-1942  19
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Study Period Screening Intervention (Days)aPost-Treatment 
Safety 
MonitoringPost-
study
Scheduled DayUp 
to 
day    
-35-
2-
11 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 42
Inclusion/Exclusion 
CriteriaX X
DomicilingfX----------- -------------------------------------------------------------------------------------------------- --------------------------------------------------- X
Assignment of 
allocation numberX
Standard MealsgX----------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------- X
Treat ment Administration
MK-1942 or 
Placebo 
AdministrationhDose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 (Provisional) 
Donepezil 
Administrationi X ------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- X
Safety Monitoring
Vital Signs (heart 
rate, blood 
pressure, 
respiratory rate, 
body temperature)j, 
kX X XX X X X X X X X X X X X X X X X X X X X X X
Orthos tatic VS 
(heart rate, blood 
pressure)j,lX X X X X X X X X X X X
12-lead ECGmX XXXX X X XXX X X X XX X X XXX X X X X
Hematology, 
Chemistry, 
UrinalysisnX X X X X X X X
AE/SAE Review X---------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------- X
Targeted 
Neurological 
ExaminationoX X X X X X X X X X X X X X
C-SSRS SLApX X X X X X X
087PVJ
PRODUCT: MK-1942  20
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Study Period Screening Intervention (Days)aPost-Treatment 
Safety 
MonitoringPost-
study
Scheduled DayUp 
to 
day    
-35-
2-
11 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 42
Phar macokinetic Sampling
Blood for Plasma 
MK-1942 assayq XX X XX X X XX X X XX X X X X X X
Blood for Plasma 
Donepezil Assayr XX X X
Biom arkers
Blood for Genetic 
Analysiss X
aIf Dose Level 4 is not administered, procedures scheduled for Days 28 -30 should be timed relative to the AM dose administered on Day 21.
bPE on Day 30 should be conducted ~ 48 hrs after the last dose administered on Day 28.
cMay be done upon arrival in the CRU.
dAssessments on Day 28 should be given within 12 hours of the last morning do se.
eApractice assessment will be administered a t screening. The assessment given on Day -1 will provide the baseline value . On Days 14 and 28 , assessments should be given within 
4 hours after the AM dose. See study operation’s manual for specific 
instructions on test administration.
fPatients will be domiciled the entire 21 -28 D of treatment, with 4additional overnight stays ( Days -2, -1, 29, 30) for pre-treatment baseline, PK assessments and for 
post-
treatment safety monitoring.  Patients may le ave the CRU on Days 5, 6 of each dosing level at the discretion of the PI, with at -home safety and compliance monitoring.
gPatients may be provided a meal on Day 31 prior to discharge.
hPatients will take the first dose of MK -
1942/placebo in the AM along with daily donepezil treatment.  Patients will be dosed BID with MK -1942/placebo, except on Day 28, 
when only the morning dose is administered.  If Dose Level 4 is not given, only the AM dose of Dose Level 3 will be given on Day 21.
i Patients will take their personal donepezil prescription QD in the AM. Those patients who do not take donepezil in the AM should be advised to st art morning dosing on Day -7.
jVS measures out of normal range will be repeated up to 3 times in 15 minutes, or until measures ret urn to normal.
kDays 1, 7, 8, 14, 15, 21, 22, and 28 are intense monitoring days :Single measures of semi -
recumbent HR and BP to be taken predose (triplicate on Day 1), 2 and 4 hrs after the 
AM dose . Days -1, 2, 3, 4, 9, 10, 11, 16, 17, 18, 23, 24, and 25 : Single measures of HR and BP to be taken predose and ~ 2 hrs after the AM dose. Days 29 and 30: HR and BP to 
be taken at ~ 24 and 48 hrs postdose relative to Day 28, respectively. Single measures of RR, BT taken predose on Day 1 and ~ 2 hrs after the AM dose on Days 1, 7, 8, 14, 15, 21, 
22 and 28.
lDays 1, 7, 8, 14, 15, 21, 22, and 28: Orthostatic HR and BP to be taken pre -
dose on Day 1 and ~ 2 hrs after the AM dose. Days 29 and 30: orthostatic measures can be taken at ~ 
24 and 48 hrs relative to post -dose Day 28. 
mAll ECGs will be measured in triplicate. Days 1, 7, 8, 14, 15, 21, 22, and 28 are intense monitoring days : predose and ~ 1, 2, 3, 4, 6, 8, and12hours after the AM d ose.Days 2, 
3, 4, 9, 10, 11, 16, 17, 18, 23, 24, and 25:
predose and ~ 2 hours after the AM dose. Days 29and 30: ~ 24 and 4 8 hrs after the Day 28 dose.
nDays
-1,8, 15, 22, and 28: ~ 2 hrs after the AM dose of donepezil . Day 30: ~ 48 hrs after the Day 28 dose.
oDays -1
,1: ~ 1.5 hours after AM dose of donepezil. Days 4, 7, 8, 11, 14, 15, 18, 21, 22, 25, and 28: ~ 1.5 hours after AM dose, or more frequently as required by investigator. 
Day 29: ~ 24 hrs after AM dose Day 28.
pDay 1: before AM dose. Days 8, 15, 22, and 28: ~ 4 hrs after the AM dose. Day 30: ~ 48 hrs after the AM dose on Day 28.
087PVJ
PRODUCT: MK-1942  21
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Study Period Screening Intervention (Days)aPost-Treatment 
Safety 
MonitoringPost-
study
Scheduled DayUp 
to 
day    
-35-
2-
11 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 42
qDays 1, 7, 14, 2 1, and 28 are intense PK sampling days. Blood samples will be taken predose, and at 0.5, 1, 2, 3, 4, 6, and 12 hours post AM dose. On Day 28 (or last day of 
dosing), administer the AM dose only and sample predose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, and 72 hr p ost-dose. On Days 2, 4, 8, 9, 11, 15,16, 18, 22, 23, and 25 a sample will be taken 
before the AM dose (Ctrough).   
rDays -
1 and 28areintense PK sampling days .Samples to be taken pre -dose and 0.5, 1, 2, 3, 4, 6, 12 and 24 hrs post -dose. On Day -1 time p oints are relative to the morning 
donepezil dose. If Dose Level 4 is not given, Day 21 will be the second intense PK sampling day instead of Day 28. 
s Pre-dose from enrolled participants only –See Section 8.8.
087PVJ
PRODUCT: MK-1942  22
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
2 INTRODUCTION
 
 
 
AD is a progressive neurodegenerative disorder 
chara cterized b y the loss of neurons from the cerebral cortex and hippocampus, and of 
cholinergic neurons in the nucleus basalis,  
 
 
 
 
 
 
2.1 Study Rationale
This study  has the following goals :tofurther explor edoses of MK -1942 
to evaluate 
the potential for the combination sof MK -1942 and donepezil to i ncrease the incidence or 
severit y of AEs characteristic of either agent, or the appearance of new ones
;to observe any 
effects of the combination of donepezil and MK- 1942 on the PK of either agent in AD 
patients . 
Regarding theseinteractions, p revious clinical studies indicate that the primary  AEs observed 
following MK -1942 administration are dizziness, headache and nausea of mild to moderate 
severit y, with infrequent reports of gait abnormalities, visual disturbances, and emesis .  Some 
of these sy mptoms are held in common with the AE profile of donepezil, which is 
characterized b y nausea, dizziness, diarrhea, em esis, muscle cramps, fatigue, brad ycardia and 
syncope . Because t he incidence and/or severity of these AEs may  be aggravated upon co -
administration of donepezil with MK -1942, the possibility  of such an interaction will be 
evaluated b y administering a poten tially  efficacious dosing regimen of MK -1942 to a panel 
of AD patients stabl y maintained on donepezil (≥10-mg, ≤15-mg) as part of their treatment 
for cognitive impairment.
In addition to the potential effects of MK -1942 and donepezil co-administration , patients 
with AD frequently  exhibit unsteady  gait, contributing to an increased propensity  for falls
[O'Keeffe, S. T., et al 1996] . The incidence of falls may be worsened by  MK -1942 treatment 
at efficacious dose le velsdue to increased episodes of dizziness and/or gait disturbances . 
Therefore, administering MK -1942 to a population of AD patients receiving donepezil is 
CCI
CCI
CCI
CCI
087PVJ
PRODUCT: MK-1942  23
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
justified for determining whether an interaction of the two drugs may  alter their general 
tolerabil ityor PK .  
2.2 Background
Refer to the IB for detailed background information on MK -1942.
2.2.1 Pharmaceutical and Therapeutic Background
 
When administered to rhesus monkeys in the scopolamine -impaired object retrieval 
assessment, MK -1942 improved cognitive performance  
 
 
.  These effects on cognition are consistent with those observed with other, 
structurally  diverse , both across species (mice, rats, rhesus and African 
Green monkey s) and cognitive domains (attention, working memory , episodic memory  and 
executive function). 
2.2.2 Preclinical and Clinical Studies
Please refer to the Investigator’s Brochure for detailed information on the preclinical and 
clinical studies to date involving MK -1942.
2.2.3 Ongoing Clinical Studies
2.2.3.1 MK-1942 -002: A Double -Blind, Placebo- Controlled, Multiple Ascending
Dose Study of the Safety, Tolerability and Pharmacokinetics of MK -1942 in 
Healthy Participants
MK-1942- 002 evaluat edthe safet y and PK of multiple oral doses of MK -1942  
 
 
.
Participants are being randomized to one of 6 panels, wit h active and placebo treatments 
being administered in a 3:1 ratio.  
CCI
CCI
CCI
CCI
CCI
087PVJ
PRODUCT: MK-1942  24
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
The Cmax and AUC values achieved in this study  using the DFC formulation were generally  
consistent with those reached in MK- 1942- 001 with the OSF at comparable dose levels. 
 
 
 
 Accumulation was consistent with the apparent terminal
hours, indicating that the PK of MK -1942 is not time dependent. 
Plasma concentrations associated with the highest dosing levels (Panels E, F) [ Figure 2] were 
generall y consistent with the BID dosing data from previous panels.  
 
CCI
CCI
CCI
087PVJ
PRODUCT: MK-1942  25
PROTOCOL/AMENDMENT NO.: 005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Table 2 Summary  of the Pharmacokinetic Parameters of MK -1942 Following Administration of Multiple Ascending Oral Doses to
Health y Adult Subjects
CCI
087PVJ
PRODUCT: MK-1942  26
PROTOCOL/AMENDMENT NO.: 005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
CCI
087PVJ
PRODUCT: MK-1942  27
PROTOCOL/AMENDMENT NO.: 005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
CCI
087PVJ
PRODUCT: MK-1942  28
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Figure 2Mean (SD) Plasma Concentration Time Profiles for MK -1942 Following 
Administration of Multiple Oral Doses to Healthy  Adult Subjects in Panels E and F (red) 
from Study  MK-1942 -002. (Top; L inear Scale, Bottom; L og-linear Scale)
Of the 48 total participants treated in Panels A -F, 42 reported one or more AEs. One 
participant experienced 2 episodes of moderate nausea lasting 3 hours and 15 minutes, and 2 
cases of vomiting lasting 5 and 10 minutes on days 3 and 4 of dosing. This individual 
withdrew consent for additional dosing but completed the remainder of the study monitoring 
tasks and follow -up. The second participa nt experienced one episode of moderate nausea 
lasting 15.5 hours accompanied b y 10 minutes of vomiting on day 4 of dosing. This was 
followed on day  5 of dosing b y an episode of mild nausea lasting 17.2 hours. This individual 
continued the dosing regimen and completed the study .   Otherwise, the treatment has been 
safe and generally  well -tolerated, with no clinically significant, treatment -related 
abnormalities in: VS (HR, SBP, DBP, RR, BT); ECG; blood chemistry ; hematology; 
neurological exams; phy sical exam s; or behavior (suicidality ). The most commonly  reported 
AEs ( ≥2 subjects) due to all causes are: dizziness (20), headache (17), nausea (9), 
nasophary ngitis (5), diarrhea (4), sensory  processing disorder (4), abdominal pain (4), 
vomiting (3), increased SBP (2), dry  mouth (2) palpitations (2), abdominal discomfort (2), 
dizziness postural (2), hot flush (2), and neutropenia (2) [ Table 3 ]. 
The incidence and severity  of dizziness episodes appeared to decrease with repeated 
administration over 5 -10 day s at a given dose level.   
CCI
CCI
087PVJ
PRODUCT: MK-1942  29
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
 
 
 These results suggest that tolerance 
to dizz iness and headache could be elicited b y titrating doses of MK -1942 by  BID 
administration over 7 days /dose level .
CCI
087PVJ
PRODUCT: MK-1942  30
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Table 3 Subjects Reporting Adverse Events (Incidence > 0% in One or More Treatment Groups)
Screening Panel A Panel B Panel C Panel D 
n (%) n (%) n (%) n (%) n (%) 
Subjects in population                                               48                                                                            8                                                                            8                                                                            8                                                                            8                                                                            
   with one or more adverse events                                    1                                    (2.1)                                    5                                   (62.5)                                   6                                   (75.0)                                   6                                   (75.0)                                   5                                   (62.5)                                   
   with no adverse events                                             47                                   (97.9)                                   3                                   (37.5)                                   2                                   (25.0)                                   2                                   (25.0)                                   3                                   (37.5)                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Blood and lymphatic system disorders                             0                               (0.0)                                0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                
   Eosinophilia                                                       0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Neutropenia                                                        0                                    (0.0)                                    0                                   (0.0)                                    0           (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
Cardiac disorders                                                0                               (0.0)                                0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                
   Palpitations                                                       0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Supraventricular extrasyst oles                                     0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
Eye disorders                                                    0                               (0.0)                                0                              (0.0)                                0                      (0.0)                                1                              (12.5)                               0                              (0.0)                                
   Vision blurred                                                     0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    
Gastrointestinal disorders                                       0                               (0.0)                                2                              (25.0)                               2                              (25.0)                               0                              (0.0)                                3                              (37.5)                               
   Abdominal discomfort                                               0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Abdominal pain                                                     0                                    (0.0)                                    1                                   (12.5)                                   1                                   (12.5)                                   0                                   (0.0)                                    0                                   (0.0)                                    
   Diarrhoea                                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
   Dry mouth                                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
   Dyspepsia                                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Nausea                                                             0                                    (0.0)                                    1                                   (12.5)                                   1           (12.5)                                   0                                   (0.0)                                    1                                   (12.5)                                   
   Vom iting                                                           0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
General disorders and administration site 
conditions             0                               (0.0)                                0                              (0.0)                                1                              (12.5)                               0                              (0.0)                                0                              (0.0)                                
   Chest discomfort                                                   0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
087PVJ
PRODUCT: MK-1942  31
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
SUBJECTS WI TH ADVERS E EVENTS 
(INCIDENCE > 0% IN O NE OR MORE TREATMENT GROUPS)
Panel E Panel F Placebo Follow -Up 
n (%) n (%) n (%) n (%) 
Subjects in population                                               8                                                                            8                                                                            8                                                                             48                                                                            
   with one or more adverse events                                    6                                   (75.0)                                   6                                   (75.0)                                   8                                   (100.0)                                   1                                    (2.1)                                    
   with no adverse events                                             2                                   (25.0)                                   2                                   (25.0)                                   0                     (0.0)                                     47                                   (97.9)                                   
                                                                                                                                                                                                                                                                                                                                                                                                              
Blood and lymphatic system disorders                             0                              (0.0)                                1                              (12.5)                               0                              (0.0)                                 1                               (2.1)                                
   Eosinophilia                                                       0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                     0           (0.0)                                    
   Neutropenia                                                        0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                     1                                    (2.1)                                    
Cardiac disorders                                                2                              (25.0)                               1                              (12.5)                               0                              (0.0)                   0                               (0.0)                                
   Palpitations                                                       1                                   (12.5)                                   1                                   (12.5)                                   0                                   (0.0)                                     0                                    (0.0)                                    
   Supraventricular extrasystoles                                     1                                   (12.5)                                   0                                   (0.0)                                    0                     (0.0)                                     0                                    (0.0)                                    
Eye disorders                                                    0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                 0                               (0.0)                                
   Vision blurred                                                     0                                   (0.0)                                    0                                   (0.0)                                    0                     (0.0)                                     0                                    (0.0)                                    
Gastrointestinal disorders                                       3                              (37.5)                               5                              (62.5)                               1                              (12.5)                                0                               (0.0)                                
   Abdominal discomfort                                               0                                   (0.0)                                    1                                   (12.5)                                   1                     (12.5)                                    0                                    (0.0)                                    
   Abdominal pain                                                     0                                   (0.0)                                    2                                   (25.0)                                   0                                   (0.0)                                     0                                    (0.0)                                    
   Diarrhoea                                                          2                                   (25.0)                                   1                                   (12.5)                                   0                                   (0.0)                                     0                                    (0.0)                                    
   Dry mouth                                                          1                                   (12.5)                                   0                                   (0.0)                                    0                     (0.0)                                     0                                    (0.0)                                    
   Dyspepsia                                                          1                                   (12.5)                                   0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Nausea                                                             2                                   (25.0)                                   4                                   (50.0)                                   0                                   (0.0)                                     0                                    (0.0)                                    
   Vom iting                                                           2                                   (25.0)                                   0                                   (0.0)                                    0                     (0.0)                                     0                                    (0.0)                                    
General disorders and administration site conditions             0                              (0.0)                                2                              (25.0)                               0                              (0.0)                                 0                               (0.0)                                
   Chest discomfort                                                   0                                   (0.0)                                    1                                   (12.5)                                   0                     (0.0)                                     0                                    (0.0)                                    
087PVJ
PRODUCT: MK-1942  32
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
SUBJECTS WI TH ADVERS E EVENTS 
(INCIDENCE > 0% IN O NE OR MORE TREATMENT GROUPS)
Screening Panel A Panel B Panel C Panel D 
n (%) n (%) n (%) n (%) n (%) 
General disorders and administration site 
conditions             0                               (0.0)                                0                              (0.0)                                1                      (12.5)                               0                              (0.0)                                0                              (0.0)                                
   Chest pain                                                         0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Gait disturbance                                                   0                                    (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    0                                   (0.0)                                    
Infections and infestations                                      0                               (0.0)                                1                              (12.5)                               0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                
   Nasopharyngitis                                                    0                                    (0.0)                                    1                                   (12.5)                                   0                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Pharyngit is                                                        0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
Injury, poisoning and procedural 
complications                   0                               (0.0)                                0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                1                              (12.5)                               
   Contusion                                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
   Procedural pain                                                    0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
Investigations                                                   0                               (0.0)                                0                              (0.0)                                0                              (0.0)                                1                              (12.5)                               0                              (0.0)                                
   Blood potassium inc reased                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    
   Blood pressure diastolic i ncreased                                 0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Blood pressure systolic increased                                  0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Electrocardiogram QRS complex prolonged                            0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
Musculoskeletal and connective tissue 
disorders                  0                               (0.0)                                0                              (0.0)                                0                              (0.0)                                1                              (12.5)                               1                              (12.5)                               
   Back pain                                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    
   Muscular weakness                                                  0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Musculoskeletal stiffness                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
   Neck pain                                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
087PVJ
PRODUCT: MK-1942  33
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
SUBJECTS WI TH ADVERS E EVENTS 
(INCIDENCE > 0% IN O NE OR MORE TREATMENT GROUPS)
Panel E Panel F Placebo Follow -Up 
n (%) n (%) n (%) n (%) 
General disorders and administration site conditions             0                              (0.0)                                2                              (25.0)                               0                              (0.0)                                 0                               (0.0)                                
   Chest pain                                                         0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                     0                                    (0.0)                                    
   Gait disturbance                                                   0                                   (0.0)                                    0                                   (0.0)                                    0                     (0.0)                                     0                                    (0.0)                                    
Infections and infestations                                      1                              (12.5)                               1                              (12.5)                               3                              (37.5)                                0                               (0.0)                                
   Nasopharyngitis                                                    1                                   (12.5)                                   0                                   (0.0)                                    3                     (37.5)                                    0                                    (0.0)                                    
   Pharyngitis                                                        0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                     0                                    (0.0)                                    
Injury, poisoning and procedural complications                   0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                 0                               (0.0)                                
   Contusion                                                          0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Procedural pain                                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
Investigations                                                   1                              (12.5)                               1                              (12.5)                               1                              (12.5)                                0                               (0.0)                                
   Blood potassium increased                                          0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Blood pressure diastolic increased                                 0                                   (0.0)                                    0                                   (0.0)                                    1                     (12.5)                                    0                                    (0.0)                                    
   Blood pressure systolic increased                                  1                                   (12.5)                                   0                                   (0.0)                                    1                                   (12.5)                                    0                                    (0.0)                                    
   Electrocardiogram QRS complex prolonged                            0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                     0                                    (0.0)                                    
Musculoskeletal and connective tissue disorders                  0                              (0.0)                                0                              (0.0)                                2                              (25.0)                                0                      (0.0)                                
   Back pain                                                          0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Muscular weakness                                                  0                                   (0.0)                                    0                                   (0.0)                                    1                     (12.5)                                    0                                    (0.0)                                    
   Musculoskeletal stiffness                                          0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Neck pain                                                          0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                    0                                    (0.0)                                    
087PVJ
PRODUCT: MK-1942  34
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
SUBJECTS WI TH ADVERS E EVENTS 
(INCIDENCE > 0% IN ONE OR MORE TREAT MENT GROUPS)
Screening Panel A Panel B Panel C Panel D 
n (%) n (%) n (%) n (%) n (%) 
Nervous system disorders                                         0                               (0.0)                                3                              (37.5)                               5                      (62.5)                               5                              (62.5)                               3                              (37.5)                               
   Balance disorder                                                   0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Dizziness                                                          0                                    (0.0)                                    3                                   (37.5)                                   5                                   (62.5)                                   3                                   (37.5)                                   2                                   (25.0)                                   
   Dizziness postural                                                 0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    
   Head discomfort                                                    0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
   Headache                                                           0                                    (0.0)                                    1                                   (12.5)                                   2           (25.0)                                   4                                   (50.0)                                   1                                   (12.5)                                   
   Sensory disturbance                                                0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    
   Sensory processing disorder                                        0                                    (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   1                                   (12.5)                                   0                                   (0.0)                                    
   Somnolence                                                         0                                    (0.0)                                    0                                   (0.0)                                    0           (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Tunnel vision                                                      0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
Psychiatric disorders                                            0                               (0.0)                                1                              (12.5)                               1                              (12.5)                               0                              (0.0)                                0                              (0.0)                                
   Listless                                                           0                                    (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Staring                                                            0                                    (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    0                                   (0.0)                                    
Renal and urinary disorders                                     0                               (0.0)                                0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                1                              (12.5)                               
   Leukocyturia                                                       0                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
   Nocturia                                                           0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
Respiratory, thoracic and mediastinal 
disorders                  1                               (2.1)                                0                              (0.0)                                0                              (0.0)                                1                              (12.5)                               0                              (0.0)                                
   Nasal congestion                                                   1                                    (2.1)               0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    
Skin and subcutaneous tissue disorders                           0                               (0.0)                                0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                2                              (25.0)                               
   Eczema                                                             0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1            (12.5)                                   
   Pruritus                                                           0                                    (0.0)                                    0           (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   
087PVJ
PRODUCT: MK-1942  35
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
SUBJECTS WI TH ADVERS E EVENTS 
(INCIDENCE > 0% IN O NE OR MORE TREATMENT GROUPS) 
Panel E Panel F Placebo Follow -Up 
n (%) n (%) n (%) n (%) 
Nervous system disorders                                         4                              (50.0)                               6                              (75.0)                               4                              (50.0)                                0                               (0.0)                                
   Balance disorder                                                   0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                    0                                    (0.0)                                    
   Dizziness                                                          1                                   (12.5)                                   6                                   (75.0)                                   0                     (0.0)                                     0                                    (0.0)                                    
   Dizziness postural                                                 0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                     0                                    (0.0)                                    
   Head discomfort                                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Headache                                                           3                                   (37.5)                                   3                                   (37.5)                                   3                     (37.5)                                    0                                    (0.0)                                    
   Sensory disturbance                                                0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Sensory processing disorder                                        0                                   (0.0)                                    2                                   (25.0)                                   0                                   (0.0)                                     0                                    (0.0)                                    
   Somnolence                                                         0                                   (0.0)                                    1                                   (12.5)                                   0                     (0.0)                                     0                                    (0.0)                                    
   Tunnel vision                                                      0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                     0                                    (0.0)                                    
Psychiatric disorders                                            0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                 0                               (0.0)                                
   Listless                                                           0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Staring                                                            0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
Renal and urinary disorders                                      0                              (0.0)                                0                              (0.0)                                1                              (12.5)                                0                               (0.0)                                
   Leukocyturia                                                       0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Nocturia                                                           0                                   (0.0)                                    0                                   (0.0)                                    1                     (12.5)                                    0                                    (0.0)                                    
Respiratory, thoracic and mediastinal disorders                  0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                 0                               (0.0)                                
   Nasal congestion                                                   0                                   (0.0)                                    0                                   (0.0)                                    0                     (0.0)                                     0                                    (0.0)                                    
Skin and subcutaneous tissue disorders                           0                              (0.0)                                0                              (0.0)                                0                              (0.0)                                 0                               (0.0)                                
   Eczema                                                             0                                   (0.0)                                    0                                   (0.0)                                    0                     (0.0)                                     0                                    (0.0)                                    
   Pruritus                                                           0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
087PVJ
PRODUCT: MK-1942  36
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
SUBJECTS WI TH ADVERS E EVENTS 
(INCIDENCE > 0% IN O NE OR MORE TREATMENT GROUPS) 
Screening Panel A Panel B Panel C Panel D 
n (%) n (%) n (%) n (%) n (%) 
Vascular disorders                                               0                               (0.0)                                0                              (0.0)                                0                              (0.0)                                1                              (12.5)                               0                              (0.0)                                
   Haematoma                                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                   0                                   (0.0)                                    
   Hot flush                                                          0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Hypertension                                                       0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
   Orthostatic hypotension                                            0                                    (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                    
SUBJECTS WI TH ADVERS E EVENTS 
(INCIDENCE > 0% IN O NE OR MORE TREATMENT GROUPS)
Panel E Panel F Placebo Follow -Up 
n (%) n (%) n (%) n (%) 
Vascular disorders                                               1                              (12.5)                               1                              (12.5)                               2                              (25.0)                                0                               (0.0)                                
   Haematoma                                                          0                                   (0.0)                                    0                                   (0.0)                                    0                                   (0.0)                                     0                                    (0.0)                                    
   Hot flush                                                          1                                   (12.5)                                   1                                   (12.5)                                   0                     (0.0)                                     0                                    (0.0)                                    
   Hypertension                                                       0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                    0                                    (0.0)                                    
   Orthostatic hypotension                                            0                                   (0.0)                                    0                                   (0.0)                                    1                                   (12.5)                                    0                                    (0.0)                                    
Every subject is counted a single time for each applicable row and column.
A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns mee ts the incidence criterion in the report title, after 
rounding.
QD=once a day; BID=twice a day
Adverse event terms are from MedDRA Version 22.0
Source:  [P002V01MK1942: adam -adsl; adae]
CCI
087PVJ
PRODUCT:   MK-1942  37
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
2.2.3.2 MK-1942 -004: A Randomized, Double Blind, Placebo- Controlled 
Investiga tion of the Safety, Tolerability and Pharmacokinetics of Multiple-
Dose Regimens of MK -1942 in Healthy Elderly Participants
MK-1942- 004 is a stud y of the safet y and PK of MK -1942 when administered as multiple 
dose regimens. The stud y consists of 3 panels, with Panels A and C each comprised of 8 
healthy  elderl y participants of both genders and Panel B consisting of 8 healthy adults of 
both genders receiving either MK-1942 (N=6) or placebo (N=2). Participants will be enrolled 
in only  one panel of the study . All participant s aredomiciled during the treatment period 
(Panel A: 21 day s, Panel s Band C : up to 28 days) and for 2daysafter completion of dosing 
for safety  monitoring (Table 5). The stud y will employ multiple dose and titration dosing 
regimens of varying dose levels (not to exceed 50-mg), dosing frequencies (not to exceed 
BID) and dosing durations (up to 28days in total) .
CCI
087PVJ
PRODUCT:   MK-1942  38
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
Table 5 Proposed Dosing Regimens for MK-1942- 004-001
Panel APK 
BreakBPK 
BreakC
Treatment 5-mg 
BID 
x 7D10-mg
BID x 
7 D20-mg 
BID x 
7D3 
weeks8-mg 
BID 
x 7D15-mg 
BID x 
7D30-mg 
BID x 
7D50-mg 
BID x 
7D3 
weeks8-mg 
BID 
x 7D15-mg 
BID x 
7D30-mg 
BID x 
7D50-mg 
BID x 
7D
Abbreviations: BID= bis -in-diem  (twice daily); D=day; PK= pharmacokinetics
As of 4 March , 2020, 8 subjects in Panel A completed the dosing regimen outlined in Table 
5.  In addition, 8 healthy  adult subjects underwent treatment in Panel B.  Although data from 
both panels remains under blind, no SAEs or discontinuations were reported from panel A .  
Those AEs reported, primarily  lightheadedness andheadache ,are reversible and of mild 
severit y
.  Of the 8 subjects in Panel B, 3 individuals reported multiple episodes of dizziness, 
headache and tinnitus of mild severity  during treatment at dose level 2 (15 mg ID/pbo, day s 
8-14 of treatment ).  Two of the three individuals continued dosing at 15 mg ID/pbo for an 
additional week (day s 15-21 of treatment) in lieu of escalation to dose level 3, 30 mg ID/pbo.  
After completing the second week of treatment with 15 mg ID /pbo, both participants 
withdrew themselves from the study  (day  22 of treatment).  The third subject withdrew from 
the study  on day  15 of treatment after having received one additional dose of 15 mg.  None 
of these 3 participants met individual stop dosing criteria for the severity  of dizziness or 
nausea.  The remaining 5 participants completed all 4 dose levels up to 50 mg ID/pbo.  A 
single episode each of drowsiness and lightheadedness were reported b y 2 of those subjects 
at dose level 3 (30 mg ID/pbo).  The same two subjects each reported a single episode of 
lightheadedness and headache at dose level 4 (50 mg ID/pbo).  One subject reported a brief
(5 min) episode of emesis on day 23 of treatment at dose level 4, but continued dosing at this 
level until to the end of the study.
Overall, there were no clinically  significant changes in VS, ECG, targeted neurological 
exams, lab chemistry , hematology  or urinaly ses manifested b y any participant at an y point 
during the stud y. There were no SAEs or severe, non -serious AEs observed.  Stop dosing 
criteria were not achieved during Panels A, B.  Enrollment of Panel C is initiating using the 
dosing regimen described in Table 5 .
2.2.4 Infor mation on Other Study -related Therapy
Donepezil Hydrochloride (HCl)
Donepezil HCl is an AChEI  that is marketed for sy mptomatic treatment of mild -to-moderate 
cognitive impairment associated with AD. The s tandard oral dos eof donepezil HCl is one 10 
-mgtablet daily . The most common AE s associated with donepezil HCl administration 
(occurring at a frequency of ≥5% and at twice the placebo rate at the 10- mgQD dose) are 
consistent with its cholinomimetic effects andinclud enausea, diarrhea, insomnia, vomiting, 
muscle cramps , fatigue and anorexia. These AEs are mild in intensity and transient , typically  
resolving with continued donepezil HCl treatment without the need for dose adjustment 
[Jackson, S., et al 2004] . Less commonly observed AEs include depression and sleep 
disturbances (eg, abnormal dreams and somnolence).
087PVJ
PRODUCT:   MK-1942  39
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
Donepezil HCl is ~96% bound to human plasma proteins over the concentration range of 2 to 
1000 ng/mL. It is extens ively  metabolized by  the CYP 450 isoenzy mes 2D6 and 3A4, 
undergoes glucuronidation, and is excreted in the urine as the parent compound, four major 
metabolites (two of which are known to be active ), and several incompletely  identified, 
minor metabolites. D onepezil HCl has a Tmax of ~3 to 4 hours and half -life ~70 hours.
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical trials will directly benefit from treatment 
during participation as clinical trials are designed to provide info rmation about the safet y and 
effectiveness of an investigational medicine.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompanyi ng IB and informed consent documents.
3 H YPOTHESE S, OBJECTIVES ,AND ENDPOINTS
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
Details of the h ypotheses to be tested can be found in Section 9.3.
Objectives Endpoints
Primary
•Evaluate the safet y and tolerability of 
treatment ( MK-1942 co-administered
with donepezil )inAD patients with mild -
to-moderate cognitive impairment.•Safety  measures (VS, ECGs, clinical 
chemistry , hematology , urinaly sis, 
targeted neurological exams, Columbia 
suicide severit y rating scale) and 
Adverse Event reports
Secondary
•Evaluate the effects of donepezil on the 
PK of MK -1942 in AD patients
Hypothes is
oThe plasma Cmax of MK -1942 
determined on the last day of a 
titrated treatment regimen (Day  21 
[28]) when co -administered with 
donepezil to AD patients is similar 
to the Cmax obtained following 
administration of MK -1942 to 
HEV from MK -1942 -004, Panel 
C. That is, the true GMR (MK-
1942 + donepezil in AD / MK-
1942 in HEV) is contained within
the interval (0.5, 2.0).•Cmax, AUC0 -12, AUC0- 24, Ctrough, 
Tmax, apparent terminal t1/2, CL ss
/F, 
and Vzss/F of MK -1942
•AUC0 -24, Cmax, Ctrough, Tmax for 
donepezil
087PVJ
PRODUCT:   MK-1942  40
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
Objectives Endpoints
•Evaluate the effects of MK -1942 on the 
PK of donepezil in AD patients. 
Estimation: 
oThe true GMRs of plasma PK 
parameters (AUC0- 24, Cmax) for 
donepezil before and during 
administration of donepezil + 
MK-1942 to AD patients will be 
estimated.
Tertiary /Exploratory
•Evaluate the changes in cognitive 
function of AD patients by comparing the 
MMSE -2 and DSST scores obtained at 
baseline with those from the last day of 
dosing. 
•Explore the relationship between plasma 
concentrations of MK -1942 and corrected 
QTintervals.
•
•Explore the relationship sbetween genetic 
variation, response to the treatment(s) 
administered, and mechanisms of disease. 
Variation across the human genome may  
be anal yzed for association with clinical 
data collected in the study.•MMSE - 2scores 
•DSST scores
•QTcF
Germline genetic variation
4 S TUDY DESIGN
4.1 Overall Design
This is a randomized, placebo- controlled, multi- site, double -blinded study  of the safet y, 
tolerability  and PK of MK -1942 when co-administered with donepezil .  Specificall y, the 
study  will evaluate the safety and PK of a selected MK -1942 titration dosing regimen 
administered to AD patients with mild cognitive impairment currently being treated with a 
stable dose of donepezil ( ≥10-mg, ≤15-mg QD).  
Participants will be domiciled starting 2 day s before treatment, during the MK -1942 
treatment period (up to 28days) and for 3days after completion of dosing for safet y 
monitoring and PK sampling ( Table 1, see Section 1.3, SoA). Participants may elect to spend 
days 5 and 6 of each dose level at home with concurrence of the PI.  Safety  and PK 
CCI
087PVJ
PRODUCT:   MK-1942  41
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
monitoring will be conducted throughout the domiciled treatment period and post -treatment 
follow -up, with safet y ensured b y monitoring AEs, VS, 12 -lead ECGs, as well as conducting 
lab safet y tests, neurological examinations, PE, and administering the C -SSRS at the times 
indicated (see Section 1.3).  The preci se timing of ECGs, blood sampling for PK, clinical and 
hematology  labs and/or other procedures listed in Section 1.3 may  be altered at any  time 
during the stud y based on newly available data .  Participants who elect to spend time at home 
will be monitored at home by  telephone to record AE episodes and treatment compliance.
The study  will employ  titration dosing regimens of vary ing dose levels (not to exceed 50-
mg), dosing frequencies (not to exceed BID) and dosing durations (up to 2 8days in total) 
(Table 1 , Figure 1). The decision to titrate doses upwards within a panel and to proceed to 
subsequent panels will be made b y the investigator with mutual agreement from the Sponsor 
based on all available safety  and PK information from previous dose levels.
The doses of MK -1942 proposed for administ ration may be adjusted in terms of dose level, 
dosing frequency  or duration, within the limits described above. Details of the decision -
making process informing dose escalation are provided in Section 6.6.
Because this is a Phase 1 assessment of MK-1942 in humans, the PK , pharmacod ynamic, and 
safet y profiles of the compound are still being elucidated. This protocol is therefore written 
with flexibility  to accommodate the inherent d ynamic nature of Pha se 1 clinical studies. 
Refer to Section 8.11.6 for examples of modifications permitted within the protocol 
parameters.
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
The objectives of this study include determin ingif the combination of MK -1942 with 
donepezil increase sthe incidence or severity  of AEs previously  reported for these agents, or 
results in unanticipated AEs in the patient population targeted for MK -1942 treatment .  In 
addition, any changes in the PK parameters of either MK -1942 or donepezil as a result of co-
administration will be assessed .
Thestudy  will investigate the effects on safet y and PK of co -administration of MK-1942 to 
AD patients with mild -to-moderate cognitive impairment who are under stable treatment 
with a treatment regimen of donepezil ( ≥10-mg, ≤15-mg).  
 
 
 
 
  Participants will be domiciled for the 
CCI
087PVJ
PRODUCT:   MK-1942  42
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
duration of treatment with the combination of donepezil and MK -1942/placebo in order to 
ensure adequate safet y monitoring and treatment compliance.
4.2.1 Rationale for Endpoints
4.2.1.1 Safety Endpoints
The safet y andtolerability of MK -1942 when administered in the multiple dose regimens 
proposed will be monitored throughout the study by collecting the following safet y 
endpoints: direct assessment/reporting of AEs; physical and neurological exams; C -SSRS 
endpoints; se mi-recumbent and orthostatic VS measures (SBP, DBP, HR, RR, BT); 12- lead 
ECG parameters; and laboratory  safet y tests (serum chemistry, hematology, and urinal ysis). 
Clinically  meaningful changes in VS and ECGs were not observed in studies MK -1942- 001, 
MK-1942- 002and MK -1942 -003 (See MK -1942 IB). However, dizziness, headache ,nausea 
and emesis of mild to moderate severity lasting < 24hours were observed following MK-
1942 administration and will be monitored using AE reports , direct observation and targeted 
neurological exams, including gait assessments taken ~2 hours post -dosing. Monitoring the 
incidence and severity  of episodes of dizziness and the application of stopping criteria, as 
well as evidence for the development of tolerance to the induction of dizz iness by MK -1942,
will form the basis for careful escalation between dose levels , thereb y minimizing the safet y 
risks for subjects participating in this study. The stopping rules ,based on observations of 
dizziness, nausea and emesis (Section 7.1.1) ,will be applied to the group on a per -panel and 
individual within
-panel basis.
ECG and VS monitoring will be scheduled in proximity  to the Cmax  
 after each dose and for up to 2 weeks after the last dose. Prior to 
starti ng treatment on Day 1, baseline VS parameters will be recorded in triplicate (Section 
8.0) and the average of each parameter will serve as a baseline for comparison to 
subsequently  recorded VS parameters. The relationship between the plasma concentration o f 
MK-1942 and ECG parameters (including QTc) will be assessed as an exploratory  objective.
The C -SSRS prospective assessment of suicidal ideation and behavior will be included in this 
study  in compliance with the 2012 FDA guidance requiring prospective ass essment in 
clinical trials conducted under IND applications and trials that are intended for submission in 
a NDA to the Neurology  or Psy chiatry  Divisions of the FDA or biologics license application, 
as well as assessment in trials that fall within the guid ance for other reasons (eg, CNS 
active/penetrant compounds, and known mechanisms or indications for which suicidal 
ideation/behavior has been previously  identified as a potential concern). The 
Baseline/Screening version of the C -SSRS will be administered a t screening, while the Since 
Last Assessment version of the C -SSRS /SLA will be given at several points during and after 
treatment administration to all subjects enrolled, including at the Post- trial visit (see Section
8.0).
In addition to regular safety  monitoring conducted during the treatment period, subjects will 
remain in the clinic for t hree additional day s of post -dose safet y monitoring and PK sampling 
at the end of the treatment period (Section 8.0) . This post-treatment period allows for plasma
CCI
087PVJ
PRODUCT:   MK-1942  43
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
MK-1942 levels to decline so that an y changes in C -SSRS endpoints resulting from a 
decrease in exposure may be manifested.  
Additional details on the safet y and toxicology of MK -1942 as determined in preclinical 
investigations are provided in the MK -1942 IB. In summary , CV and respiratory  safet y 
studies in monkey s, rats and guinea pigs noted no significant changes in VS or ECG 
parameters following exposures to MK -1942 in excess of those anticipated following 
projected efficacious doses.
In summary , preclin ical toxicology  as well as clinical safety  findings for MK -1942 suggest 
that it will be safe,  
at steady  state for the highest dose proposed in this investigation ( 50-
mg BI D). Nonetheless, the incidence and severit y of AEs observed following direct reports 
and targeted neurological exams will be recorded at multiple timepoints during the stud y to 
aid in dose escalation decisions.
Pharmacokinetic Endpoints
The plasma PK of MK -1942 following multiple dose co -administration with donepezil will 
be characterized by  determining the Cmax, Tmax, Ctrough, and AUC0 -12 after the first dose. 
In addition, Cmax, Tmax, Ctrough, AUC0 -12, AUC0 -24, apparent terminal t1/2, CL ss/F, 
Vzss/F and ac cumulation ratio will be determined at stead y state.   This will allow doses and 
dosing regimens in elderly participants with AD to be identified that produce sy stemic 
exposures in the predicted efficacious range  
 while provid ing insights into the ability  of donepezil to alter the PK of MK-
1942.
Similarly , the plasma PK of donepezil following once dail yadministration will be 
characterized b y determining the Cmax, Tmax, and AUC0 -24 on the day  before 
administration of the first dose of MK -1942 and after 21 (28 ) day s of co -administration.  
Determining the Cmax and AUC0- 24of donepezil during co -administration with MK-1942 
will provide insights into the ability  of MK-1942 to alter the PK of donepezil .
Exploratory Endpoints
The Mini -Mental State Exam, edition 2 (MMSE -2) will be administered to AD patients at 
screening and upon completion of up to 28 day sof treatment.  The score from the MMSE- 2 
given at screening will be used as an inclusion criteri on, to ensure that AD patients being 
enrolled fall into the cognitive impairment categories of mild to moderate severit y.  The 
MMSE -2 is a 30 -point examination evaluating Registration, Orientation to Time, Orientation 
to Place, Attention, Recall, L anguage, Repeti tion, Complex Commands, and Recall tasks .  A 
score between 21 to 26 typically  indicates that a subject is experiencing mild cognitive 
impairment, while scores in the range of 10-20 are indicative of patients with moderate 
cognitive impairment.  This study  proposes to enroll individuals with mild to moderate 
cognitive impairment as indicated b y scores between 17 to 26.  This range will allow for 
broader recruitment while reduc ingthe burden on CRU personnel associated with caring for 
patients with MMSE -2 sco res < 17 .  In addition to its use as a screening tool for identifying 
CCI
CCI
087PVJ
PRODUCT:   MK-1942  44
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
candidate participants as having mild to moderate cognitive impairment, the MMSE -2 will be 
used as an exploratory  endpoint to determine whether the treatment regimen results in any 
changes from the initial score.
The WAI S-R Digit Sy mbol Substitution Test ( DSST ) is a test of processing speed and 
working memory .  The DSST will be used in this study  as an exploratory  endpoint for
rapidly  assess ing whether treatment enhances cognition , as well as a safety signal for the 
development of treatment- induced cognitive decline . DSST scores from tests administered at
the middle and the end of the study  will be compared to the baseline sco re to determine if 
treatment has an y effect on cognitive function.  
4.2.1.2 Planned Exploratory Biomarker Research
4.2.1.2.1 Planned Genetic Analysis
Genetic variation may  impact a participant’s response to therap y, susceptibility  to, severit y, 
and progression of disease. Variable response to therapy ma y be due to genetic determinants 
that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and I RB/IEC allow, a sample will be collected for DNA anal ysis 
from consenting participants.
DNA samples may be used for research related to the study  intervention( s), the disease under 
study , orrelated diseases. They  may  also be used t o develop tests/assay s including diagnostic 
tests related to the disease under stud y, related diseases, and stud y intervention(s). Genetic 
research may  consist of the anal ysis of 1 or more candidate genes , the analy sis of genetic 
markers throughout the genome , or analy sis of the entire genome. Anal ysis may  be 
conducted if it is hy pothesized that this may  help further understand the clinical data.
The samples may  be analy zed as part of a multi -study  assessment of genetic factors involved 
in the response to u nderstand study  disease or related conditions.
4.2.1.3 Future Biomedical Research
The Sponsor will conduct future biomedical research on specimens fo r which consent was 
provided during this study. This research may  include genetic anal yses (DNA), gene 
expression profiling (ribonucleic acid [RNA]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on which spe cimens are consented for 
future biomedical research.
CCI
087PVJ
PRODUCT:   MK-1942  45
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consent ed participants. The objective of collecting/retaining specimens for 
future biomedical research is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the correct time. The 
details of future biomedical research are presented in Appendix 6.
4.2.2 Rationale f or the Use of Comparator/Placebo
Placebo will be used in this trial to allow for an appropriate assessment of the safet y data of 
MK-1942, an y impact of MK -1942 treatment on donepezil PK, and to maintain study  
blinding to reduce bias .
4.2.3 Rationale for Suicidal Ideation and Behavior Monitoring
Prospective assessment of suicidal ideation and behavior will be performed in this study  
using the C -SSRS. This assessment is being conducted in compliance with the 2012 FDA 
guidance requiring prospective assessment in cl inical studies conducted under IND 
applications and studies that ar e intended for submission in a NDA to the Neurology or 
Psychiatry  Divisions of the FDA or biologics license application, as well as assessment in 
studies that fall within the guidance for other reasons (eg, CNS active/penetrant compounds, 
and known mechanisms or indications for which suicidal ideation/behavior has been 
previously  identified as a potential concern).
4.3 Justification for Dose
The rationales for the doses and estimated exposures are detailed in Sections 4.3.1 and 4.3.2.
As this is a Phase 1 assessment of MK -1942 inhumans, and the PK, PD and safet y profiles 
of the compound are still being evaluated, modifications to the dose or dosing regimen may 
be required to achieve the scientific goals of the study  objectives and/or to ensure appropriate 
safet y monitoring of the study participants. Details of allowed modifications are provided in 
Section 8.11.6.
4.3.1 Starting Dose for This Study
The study  starts by administ ering 8-mg MK-1942/placebo BI D for 7 day s. This dose level 
was well -tolerated in study  MK-1942 -002, 
, similar to those observed after a single 12- mg dose. 
When this dose level followed administration of 5 -mg BID x 7D in Panel D of PN002 , it was 
associated with 4 episodes of the non-serious A Esof dizziness and headache
/head discomfort
of mild severity , resolv ingin <6 hours. Because the AEs observed with the 8- mg BID dose 
were mild and reversible and the frequency  and severity of th eseepisode s declines with 
repeated dosing over 7 days, this dose level is considered a suitable start for the titration 
CCI
087PVJ
PRODUCT:   MK-1942  46
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
dosing regimen proposed for this investigation , where each dose level increases in increments 
of approximately  2-fold.
4.3.2 Maximum Dose/Exposure for This Study
Preclinical investigations with an  analog of MK-1942 indicate that the 
cognitive performance of scopolamine -impaired NHP in the object retrieval assay  are 
maximized following a repeat dosing regimen that achieves steady -state plasma 
concentrations
 
  Given that the equivalent doses may  be required for clinically  significant 
levels of efficacy , an objective of this study  is to determine the safet y and tolerability of 
donepezil/MK -1942 co -administration using doses of MK- 1942  
 (Table 6).  The exploration of doses of MK- 1942  
 is supported by the relative safet y and tolerability of doses of 20 -mg  
 when administered in previous investigations using a titration dosing 
regimen (see Section 2.2.3.1.).
Figure 3Amelioration of Scopolamine -Induced Cognitive Impairment  
Table 6 Projected Sy stemic Exposures and Receptor Occupancies Achieved at Steady  
State with the Proposed Dose Levels. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
087PVJ
PRODUCT:   MK-1942  47
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
Because the PK parameters of MK -1942 increase linearly  in a dose -dependent fashion, data 
from protocol MK -1942- 002 ( Table 2 , Section 2.2 .3)was used to project the stead y-state 
exposures obtained following administration of higher doses of MK -1942 than previousl y 
administ ered, assuming that MK -1942 PK is similar in elderl y and non -elderly  subjects .   
 
 
 
  
 
 
 
 
 
 
. Moreover, the 50 -mg dose will only  be admin istered if 
the 30 -mg BID x 7D 
dose level is found to be safe and well tolerated , as defined by  the stop dosing criteria ( see 
Section 6.6.1) . Finall y, if the 50 -mg dose is not tolerated b y participants in MK-1942- 004, 
Panels B and C , this dose will not be administered in the provisional dose level period.
4.3.3 Rationale for Dose Interval and Study Design
MK-1942 is being developed as an adjunct to current therapies (eg, AChEI) for the treatment 
of cognitive impairment associated with Alzheimer’s dementia.  The intent of this 
investigation is to evaluate the safet y, tolerability and PK of MK -1942 when combined with 
the most commonly  prescribed AChEI, donepezil in AD patients.  Doses of donepezil
appropriate for treating cognitive impairment associated with AD wil l be co -administered 
with a dosing regimen of MK- 1942 projected to achieve potentiall y efficacious receptor 
occupancies .  These RO values are based 
on observations of the ability  of MK -1942  to reverse cognitive 
impairment in preclinical models (object retrieval performance in scopolamine -impaired 
NHP) .  The proposed regimen will also help to establish MK -1942 dosing margins for a safe 
treatment regimen. 
Clinical investigation MK -1942- 002 (Section 2.3.3) indicated that administration of 
MK-1942 BID over at lea st 7 day s was associated with a decrease in the incidence of 
episodes of dizziness, headache and other AEs . This tolerance to the adverse effects of 
MK-1942 was t ypicall y manifested after at least 5 days of dosing . 
CCI
CCI
CCI
CCI
087PVJ
PRODUCT:   MK-1942  48
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
In summary , this study  propose sthe co -administr ation of MK-1942 with donepezil, using a 
titration dosing regimen of MK -1942 BI D for 7 day s per dose level, with a maximum dose 
level of 50- mg
 
  
4.4 Beginning and End ofStudy Definition
The overall study  begins when the first participant signs the ICF. The overall study  ends 
when the last partici pant completes the last study -related telephone -call or visit, withdraws 
from the study , or is lost to follow -up (ie, the participant is unable to be contacted b y the 
investigator) .
Astudy  may  be paused during review of newl y available preclinical/ clinica l safet y, PK , 
pharmacod ynamic, efficacy , or biologic data or other items of interest, prior to a final 
decision on continuation or termination of the study. It may be necessary to keep the stud y 
open for gathering/reviewing of additional supportive data to optimally  complete the 
objective(s) of the study . If necessary , the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated. If the decision has been made to end the 
study  following this review period, the study  end willbe defined as the date of the Sponsor 
decision, and this end of study  date supersedes the definitions outlined above . The 
Competent Authority (ies) and IRB(s)/IEC(s) will be apprised of the maximum duration of 
the study  beyond the last participant out and the justifica tion for keeping the study  open.
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study  early.
Anobjective of this early Phase 1 study is to identify asafe and well -tolerated dosing 
regimen that achieve sthePK, PD, and/or biologic targets in humans based on preclinical or 
early clinical data. Therefore, it is possible that study participants may not receive all doses 
specified in the protocol if this objective is achieved at lesser dose levels. This would not be 
defined as earl y termination of the study, but rather an earlier than anticipated achievement 
of the study  objective(s). If a finding (eg, PK, pharmacod ynamic, safet y, etc.) from another 
preclin ical or clinical study  using the study  intervention(s), comparator(s), drug(s) of the 
same class, or methodology(ies) used in this study results in the study (s) or program being 
stopped for non -safet y reasons, this also does not meet the definition of earl y stud y 
termination.
Early study termination is defined as a permanent discontinuation of the study due to 
unanticipated concerns of safet y to the stud y participants arising from clinical or preclinical 
studies with the study  intervention(s), comparator(s) , drug(s) of the same class, or 
methodology (ies) used in this study .
CCI
087PVJ
PRODUCT:   MK-1942  49
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
5 STUDY POPULATION
Men and WONCBP with mild- to-moderate cognitive impairment associated with AD and
between the ages of 50 -85 (inclusive) will be enrolled this study . The degree of cognitiv e 
impairment in these candidates will be determined based on their MMSE-2 score (1 7-26) 
taken at screening. There should be no more than ~17 (~70%) p atients with MMSE- 2 scores 
consistent with mild cognitive impairment (21-26) enrolled in the trial.  Simila rly, there 
should be no less than ~7 (~30%) patients with MMSE -2 scores consistent with moderate 
cognitive impairment (17-20) enrolled in the trial .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study  if the participant :
Type of Participant and Disease Characteristics
1.Have a BMI >18 and ≤ 35kg/m2, inclusive. See Section 8.3.1 for crite ria on rounding to 
the nearest whole number. BMI = weight (kg)/height (m)2.
2.Isin good health based on medical history , physical examination, VS measures and 
ECG performed prior to randomization. 
Participants with chronic medical conditions ,including but not limited to 
hypertension, hy perlipidemia, diabetes (Ty pe 1 or 2) or hy pothy roidism ,which 
have been well -controlled on a stable dose of medication for the past two months 
and who are not receiving an y proscribed medications for treatment may be 
enrolled if clinicall y acceptable to the investigator and Sponsor. 
Section 10.8, Appendix 8 provides a table of 12 -Lead ECG Abnormality Criteria.
3.Is in good health based on laboratory  safet y tests obtained at the screening visit. 
Appendix 10.2 provides a table of laboratory safety tests to be performed. Appendix 
10.10 provides an algorithm for the assessment of out of range laboratory values.
4.Have a negative UDS prior to randomization .
5.Report a history  of cognitive and functional decline with g radual onset and slow 
progression for at least one y ear before Screening, that is either corroborated by  an 
informant who knows the subject well or is documented in medical records .
6.Have a MMSE -2 score ≥
17to ≤26at Screening, as confirmed b y the investiga tor. The 
MMSE -2 should be administered by a certified practitioner alternating the colors (red, 
blue) of the exam for a given subject to avoid learning effects with repeated 
administration.
087PVJ
PRODUCT:   MK-1942  50
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
7.Be receiving donepezil ( maximum dose: ≥10-mg, ≤15-mg) for s ymptoma tic treatment of 
cognitive impairment associated with Alzheimer’s dementia. The dose level must be 
stable for at least 1 month prior to screening. 
8.Have a reliable and competent trial partner/caregiver who has aclose relationship with 
the subject, has fac e-to-face contact at least three days a week for a minimum of six 
waking hours a week, and is willing to accompany the participant , if desired, to trial 
visits. O vernight stay s at the clinic for the partner/ caregiver are not required but may be 
requested at the discretion of investigator after consultation with the Sponsor . The trial 
partner/caregiver should understand the nature of the trial and adhere to trial requirements 
(eg, dos ing, visit schedules, and nature and number of evaluations).
Demographics
9.Ismale or female , from 50yearsto 85yearsof age inclusive, at the time of signing the 
informed consent.
Male Participants
Contraceptive use b y men should be consistent with local regulations regarding the methods 
of contraception for those participating in clinical studies.
10. Male participants are eligible to participate if they agree to the following during the 
intervention period and for at least an additional 90 day s (a spermatogenesis cy cle) after 
the last dose of study  intervention :
•Refrain from donating sperm
PLUS either:
•Be abstinent from heterosexual intercourse as their preferred and usual lifesty le (abstinent 
on a long term and persistent basis) and agree to remain abstinent
OR
•Must agree to use contraception unless confirmed to be azospermic (vasectomized or 
secondary  to medical cause [Appendix 5]) as detailed below:
-Agree to use a male condom plus partner use of an additional contraceptive method 
when having penile -vaginal intercourse with a WOCBP who is not currently  
pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain 
abstinent from penile -vaginal intercourse or use a male condom during each episode 
of penile -vaginal penetration.
087PVJ
PRODUCT:   MK-1942  51
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
Female Participants
11. A female participant is eligible to participate if: 
-She is a WONCBP, as defined in Appendix [5] .
Informed Consent
12. The participant (or legally acceptable representative if applicable) provides written 
informed consent for the study . The participant may  also provide consent for future 
biomedical research. However, t he participant may  participate in the main study  
without participating in future biomedical research.
Additional Categories
13. Is willing to comply  with the study  restrictions (see Section 5.3for a complete 
summary  of study  restrictions).
5.2 Exclusion Crite ria
The p articipant must be excluded from the study  if the participant:
Medical Conditions
1.Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
2.Is at imminent risk of self -harm, based on clinical interview and responses on the C -
SSRS, or of harm to others in the opinion of the investigator. Participants must be 
excluded if they  report suicidal ideation with intent, with or without a plan or method
(eg, positive response to item 4 or 5 in the assessment of suicidal ideation on the C -
SSRS) in the past 5 y ears or suicidal behavior in their lifetime.
3.Had major surgery , donated or lost 1 unit of blood (approximately  500 mL) within 4 
weeks prior to the p retrial (screening) visit.
4.Has a history  of clinically  significant endocrine, gastrointestinal, cardiovascular, 
hematological, hepatic, immunological, renal, respiratory , genitourinary , or major 
neurological (including stroke and chronic seizures) abnormal ities or diseases that are not 
under medical control over the past 2 months. Participants with a remote history  of 
uncomplicated medical events (eg, uncomplicated kidney  stones, as defined as 
spontaneous passage and no recurrence in the last 5 years, or ch ildhood asthma) may  be 
enrolled in the study  at the discretion of the investigator.
5.Candidates should not have a history  of asthma, COPD, urinary  obstructions or GI 
bleeding.
087PVJ
PRODUCT:   MK-1942  52
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
6.Has a history  of cancer (malignancy ).
Exceptions: (1) A dequately  treated non -mela nomatous skin carcinoma or carcinoma in 
situ of the cervix or ; (2) Other malignancies which have been successfully  treated with 
appropriate follow up and therefore unlikel y to recur for the duration of the study, in the 
opinion of the investigator and with agreement of the Sponsor (eg, malignancies which 
have been successfully  treated ≥10 years prior to the prestud y [screening ]visit).
7.Participant has an estimated eGFR ≤ 60mL/min/1.73 m2based on the MDRD.
MDRD Equation :
eGFR (mL/min/1.73 m2) = 
175 x (serum creat)-1.154x (age)-0.203x (0.742 [if female]) x (1.212 [if African American])
At the discretion of the investigator a measured creatinine clearance, as determined by a 24 -
hour urine collection, may be used in place of, or in conjunction with, the estimate of the 
eGFR.
Participants who have an eGFR or measured creatinine clearance of up to 10% below of 
either 80 mL /min (for creatinine clearance) or 80 mL /min/1.73m2 (for eGFR) may  be 
enrolled in the study  at the discretion of the investigator.
8.Has a history  of significant multiple and/or severe allergies (eg, food, drug, latex allergy), 
or has had an anaph ylactic reaction or significant intolerability  (ie, s ystemic allergic 
reaction) to prescription or non- prescription drugs or food.
9.Has evidence of a clinically  relevant or unstable psy chiatric disorder, based on DSM -5 
criteria, including schizophrenia or other ps ychotic disorder, bipolar disorder, or delirium 
at the time of the pre -study  (screening) visit, or has a history  of clinicall y significant 
psychiatric disorder of the last 5 y ears. Candidates may  be excluded if they  currentl y 
manifest Neurops ychiatric Sy mptoms of Dementia, specificall y episodes of aggression, 
emotional outbursts or agitation. Following consultation between the Investigator and the 
Sponsor, a history  of major depressive disorder, generalized anxiety  disorder, and/or 
insomnia under good control for ≥ 2 months on stable medical therap y ma y not be 
exclusionary .
Prior/Concomitant Therapy
10.All medications being taken by candidates for enrollment in the study  should be 
reviewed b y the PI and the Sponsor to determine their propensity for altering MK -1942 
exposure, or for MK -1942 to interfere with the metabolism of the medication. 
Medications prescribed for the candidate that are stably  treating a condition should not 
be interrupted. Candidates should not be enrolled if they  are taking  
 
Enrollment of candidates taking prescription 
drugs that can alter QTi for an underl ying condition (including: anti -arrhythmics 
CCI
087PVJ
PRODUCT:   MK-1942  53
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
[quinidine, procainamide, disopromide, dofetilide, sotalol], some antihistamines, 
antidepressants [tricy clics, doxepin, fluoxetine] and antimic robials) should be avoided. 
See Section 8.1.5 for more examples of excluded agents.
Prior/Concurrent Clinical Study Experience
11.Has participated in another investigational study within 4 weeks (or 5 half -lives, 
whichever is greater) prior to the prestud y (screening) visit. The window will be derived 
from the date of the last visit in the previous study.
Diagnostic Assessments
13.Has a QTc interval ≥470 msec (for males) or ≥480 msec (for fem ales) .
Other Exclusions
14.Is under the age of legal consent.
15.Is a smoker and/or has used nicotine or nicotine -containing products (eg, nicotine patch 
and electronic cigarette) within 3 months of screening.
16.Consumes greater than 3 glasses of alcoholic beverag es (1 glass is approximately  
equivalent to: beer [354 mL /12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 
mL/1 ounce]) per day . Participants who consume 4 glasses of alcoholic beverages per day  
may be enrolled at the discretion of the investi gator.
17.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately  equivalent to 120 -mgof caffeine) of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day.
18.Is a regular user of cannabis, any  illicit dru gs or has a history of drug (including alcohol) 
abuse within approximately  2years. Participants must have a negative UDS prior to 
randomization.
19.Presents an y concern b y the investigator regarding safe participation in the study or for 
any other reason the investigator considers the participant inappropriate for participation 
in the study .
2
0.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study .
CCI
087PVJ
PRODUCT:   MK-1942  54
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
5.3.1.1 Diet Restrictions
Fasting requirements for study  procedures, including but not limited to laboratory  safet y 
evaluations, are specified below.
Participants will fast for at least 8 hours prior to laboratory  safet y evaluations.
On all dosing day s,participants will fast from all food and drinks, except water, for at least 8 
hours prior to study  drug administration in the morning and for 2 hours post -dose following 
the morning and evening dose. Af ter the 2 -hour post -dose procedures have been completed, 
subsequent meals and snacks will be unrestricted in caloric content, composition and timing, 
except for dinner. Dinner must be consumed at least 2 hours prior to administration of the 
second dose of study  treatment. Participants will fast from all food and drinks except water 
between meals and snacks. The caloric content and composition of meals will be the same on 
each day  in each panel.
Water will be provided during stud y drug administration, with t he restrictions noted above. 
Water will be restricted 1 hour prior to and 1 hour after stud y drug administration.
Each stud y drug administration will need to be taken with at least 240 mL (not to exceed 500 
mL) of water.
5.3.1.2 Fruit Juice Restrictions
Participants will refrain from the consumption of grapefruit juice, grapefruits, and grapefruit 
products beginning approximately  2 weeks prior to administration of the initial dose of study  
drug, throughout the study including the washout interval between treatment periods and 
until the post -study  visit.
On full PK sampling days, participants will refrain from the consumption of all fruit juices 8 
hours prior to study  drug administration and 2 hours following the morning and evening 
dose.
On intermediate da ys and all other day s during the study , the consumption of all fruits and 
fruit juices (except for grapefruit, grapefruit juices, and grapefruit products) is allowed.
5.3.2 Caffeine, Alcohol ,and Tobacco Restrictions
5.3.2.1 Caffeine Restrictions
Participants will refra in from consumption of caffeinated beverages or xanthine -containing 
products from 8 hours prior to the pre -study  and post -study  visits. On full PK sampling day s 
participants will refrain from consumption of caffeinated beverages or xanthine -containing 
products from 8 hours prior to study  drug administration in the morning, and for 2 hours 
087PVJ
PRODUCT:   MK-1942  55
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
following the morning and evening dose. At all other times, caffeinated beverages or 
xanthine -containing products will be limited to no more than 6 units per day amounts ( >6 
units: 1 unit = 120- mg of caffeine).
5.3.2.2 Alcohol Restrictions
Participants will refrain from consumption of alcohol 24 hours prior to the pre -study  and 
post-study  visits and while domiciled on the CRU.
At all other times during the study  (screening to post -study  visit), alcohol consumption is 
limited to no more than approximately  3 alcoholic beverages or equivalent (1 glass is 
approximately  equivalent to: beer [354 mL /12 ounces], wine [118 mL /4 ounces], or distilled 
spirits [29.5 mL /1 ounce]) per day .
5.3.2.3 Tobacc o Restrictions
Smoking (and/or the use of nicotine/nicotine -containing products) is not permitted during the 
study .
5.3.3 Activity Restrictions
Participants will avoid unaccustomed strenuous physical activity (i e, weight lifting, running, 
bicycling, etc.) from t he pre -study  (screening) visit until administration of the initial dose of 
study  drug, throughout the study  (including washout intervals between treatment periods) and 
until the poststudy visit.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently randomized in the study . A minimal set of screen failure information 
may be included, as outlined in the eCRF entry  guidelines. Minimal information may  include 
demograph y, screen fail ure details, eligibility  criteria, and any AEs or SAEs meeting 
reporting requirements.
5.5 Participant Replacement Strategy
If a participant discontinues from study  intervention OR withdraws from the study a 
replacement participant may  be enrolled if deemed appropriate b y the investigator and 
Sponsor. The replacement participant will generally receive the same intervention or 
intervention sequence (as appropriate) as the participant being replaced. The replacement 
participant will be assigned a unique treatme nt/randomization number. The study  site should 
contact the Sponsor for the replacement participant’s treatment/randomization number.
The replacement participant may  begin dosing at the subsequent dose level for that panel, 
based on investigator and Sponsor review and discussion.
087PVJ
PRODUCT:   MK-1942  56
PROTOCOL/AMENDMENT N O.:  005 -01  
MK-1942 -005-01 FINAL PROTOCOL 16-MAR -2020
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or 
medical device(s) intended to be administered to a study  participant according to 
the study  protocol .
Clinical supplie s provided by  the Sponsor will be packaged to support enrollment and 
replacement participants as required. When a replacement participant is required, the Sponsor 
or designee needs to be contacted prior to dosing the replacement supplies. Clinical supplies 
will be affixed with a clinical label in accordance with regulatory requirement s.
6.1 Study Intervention(s) Administered
The study intervention(s) to be used in this study  are outlined inTable 7 .
087PVJ
PRODUCT: MK-1942  57
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Table 7 Study  Intervention s
Arm  
Nam eArm  
TypeInterven -
tion Nam eTypeDose 
Form ulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
AdministrationRegim en UseIMP/
NIMPSourcing
AD 
PatientsExperi -
mentalMK-1942 Drug Capsule 1- mg
5-mg
10-mgAll 
dosage 
levels *Oral BID 
dosing 
for up to 
28 daysExperi -
mentalIMP Provided 
centrall yby 
Sponsor
AD 
PatientsExperi -
mentalDonepezil Drug Tablet 5-mg
10-mgAll 
dosage 
levelsOral QD 
dosing 
for up to 
28 daysThera -
peuticNIMP Provided by 
participant
AD 
PatientsPlacebo Placebo to 
MK-1942Placebo Capsule N/A All 
dosage 
levelsOral BID 
dosing 
for up to 
28 daysExperi -
mentalIMP Provided 
centrally by 
Sponsor
Definition Investigational Medicinal Product (IMP) and Non -Investigational Medicinal Product (NIMP) is based on guidance issued by the European 
Commission. Regional and/or Country differences of the definition of IMP/NIMP may exist. In these circumstances, local legisl ation is followe d.
*Doses of MK -1942 m ay be adjusted based on available safety /PK data from previous panels. The required dose w ill be achieved by administering multiples of 
the available capsule strength.
087PVJ
PRODUCT: MK-1942  58
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
All supplies indicated in Table 7 will be provided per the "Sourcing" column depending upon 
local country  operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/bat ch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc).
Refer to Section 8.1.8 for details regarding administration of the study  intervention.
6.2 Preparation/Handling/Storag e/Accountability
6.2.1 Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. T he rationale for selection of doses to be used 
in this study  is provided in Section 4.3.
6.2.2 Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and an y discrepancies are 
reported and resolved before use of t he stud y intervention .
Only  participants enrolled in the study  may  receive study  intervention , and only  authorized 
site staff may  supply  or administer study  intervention . All study  intervention s must be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsibl e for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that m ust be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locall y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  the Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any applicable laws and regulations .
087PVJ
352'8&7 0. 
35272&2/$0(1'0(1712 
0.),1$/35272&2/ 0$5
,IDSDWLHQWHOHFWVWRJRKRPHGXULQJWKHDOORWWHGSHULRGDWHD FKGRVHOHYHOWKHLQYHVWLJDWRU
VKRXOGWDNHFDUHWRHQVXUHWKDWWKHVWXG\WUHDWPHQWIRUDWKRPH GRVLQJLVSDFNDJHGVRWKDWLWV
WHPSHUDWXUHLVPDLQWDLQHGDW  during transit.
 0HDVXUHVWR0LQLPL]H%LDV5DQGRPL]DWLRQDQG%OLQGLQJ
 ,QWHUYHQWLRQ$VVLJQPHQW
3DUWLFLSDQWVZLOOEHDVVLJQHGUDQGRPO\DFFRUGLQJWRDFRPSXWHU JHQHUDWHGDOORFDWLRQ
VFKHGXOHXQLTXHWRHDFKSDUWRIWKHVWXG\5HIHUWR 7DEOH
7DEOH 6DPSOH$OORFDWLRQ6FKHGXOH
1 'RVLQJ
Q  PJ0.%,'['
PJ0.%,'['PJ0.%,'['
PJ0.%,'[' 3URYLVLRQDO'RVH/HYHO 
Q  3%2WR0.%,'[>@'
 6WUDWLILFDWLRQ
1RVWUDWLILFDWLRQEDVHGRQDJHVH[RURWKHUFKDUDFWHULVWLFVZL OOEHXVHGLQWKLVVWXG\
 %OLQGLQJ
$GRXEOHEOLQGLQJWHFKQLTXHZLOOEHXVHG0.DQGSODFHERZ LOOEHSUHSDUHGDQGRU
GLVSHQVHGLQDEOLQGHGIDVKLRQE\DQXQEOLQGHGSKDUPDFLVWRUTXD OLILHGVWXG\VLWHSHUVRQQHO
7KHSDUWLFLSDQWWKHLQYHVWLJDWRUDQG6SRQVRUSHUVRQQHORUGHO HJDWHVZKRDUHLQYROYHGLQ
WKHVWXG\LQWHUYHQWLRQDGPLQLVWUDWLRQRUFOLQLFDOHYDOXDWLRQRI WKHSDUWLFLSDQWVDUHXQDZDUHRI
WKHLQWHUYHQWLRQDVVLJQPHQWV
'RQHSH]LODGPLQLVWUDWLRQZLOOEHFRQGXFWHGDVRSHQODEHOWKHUHI RUHWKH6SRQVRU
LQYHVWLJDWRUDQGSDUWLFLSDQWZLOONQRZWKHLQWHUYHQWLRQDGPLQLV WHUHG
 6WXG\,QWHUYHQWLRQ&RPSOLDQFH
,QWHUUXSWLRQVIURPWKHSURWRFROVSHFLILHGWUHDWPHQWSODQUHTXLU HFRQVXOWDWLRQEHWZHHQWKH
LQYHVWLJDWRUDQGWKH6SRQVRUDQGZULWWHQGRFXPHQWDWLRQRIWKHF ROODERUDWLYHGHFLVLRQRQ
SDUWLFLSDQWPDQDJHPHQW
 &RQFRPLWDQW7KHUDS\
,IDSDUWLFLSDQWGRHVQRWGLVFRQWLQXHDOOSULRUPHGLFDWLRQVZLW KLQGD\VRU KDOIOLYHVRI
WKHILUVWGRVHRIVWXG\LQWHUYHQWLRQKHVKHPD\EHLQFOXGHGLQ WKHVWXG\LIWKHLQYHVWLJDWRU
FDQUDWLRQDOL]HWKDWWKHVSHFLILFXVHRIDSULRUPHGLFDWLRQLV QRWFOLQLFDOO\UHOHYDQWZLWKLQWKH
FRQWH[WRIWKHVWXG\
39-
PRODUCT: MK-1942  60
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Concurrent use of an y prescription or nonprescription medication, or concurrent vaccination,
during the ongoing stud y (ie, after randomization or intervention allocation) must first be 
discussed between the investigator and Sponsor prior to administration, unless ap propriate 
medical care necessitates that therap y or vaccination should begin before the investigator and 
Sponsor can consult. The participant will be allowed to continue in the study if both the 
Sponsor and the investigator agree.
 
 
 
 
 
. Any prescribed medications used to stably  treat a screening candidate or 
enrollee should be evaluated by  the investigator in cooperation with the Sponsor to determine 
its propensity  to interact with MK -1942 in any  way  before altering the treatment or enrolling 
the candidate. A more complete list of concomitant medications that sh ould be avoided 
include:
1. Drugs that can alter QTi for an underlying condition (including: anti -arrhythmics 
[quinidine, procainamide, disopromide, dofetilide, sotalol], some antihistamines, 
and antimicrobials) should be avoided.
2. All AChEI ’s other than donepezil (phy sostigmine, neostigmine, echothiophate, 
pyridostigmine, rivastigmine, galantamine, tacrine, edrophonium, 
succiny lcholine, etc.).
3. All medications with anticholinergic effects (atropine, darifenacin, dicyclomine, 
diphenox ylate with atropine, hy droxy zine, fesoterodine, gl ycop yrrolate, 
hydroxyzine, h yoscyamine, ipratropium, ox ybutynin, promethazine, tolterodine, 
trospium, promethazine) .
4. Sedatives/benzodiazepines (eg, alprazolam, diazepam). Use of some non-
benzodiazepine medications for sleep may b e acceptable if stable for at least two 
months before the Screening Visit, following review by the Investigator and 
Sponsor .
5. Narcotic analgesics (eg, codeine, morphine, h ydromorphone, oxy codone ).
6. Thyroid hormone replacement.
7.
8. Any herbal/natural product containing St John’s wort, valerian, cassia, or licorice 
(glycyrrhizin) are restricted from use.
CCI
CCI
087PVJ
PRODUCT: MK-1942  61
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Paracetamol/acetaminophen may  be used for minor ailments without prior consultation with 
the Sponsor.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study .
6.6 Dose Modification (Escalation/Titration/Other)
6.6.1 Stopping Rules
The following stopping rules will be employ ed during the conduct of this study .
Overall dose escalation will be limited by achievement of NOAEL exposure limits, loss of 
participants due to intolerance, or completion of the scheduled dose escalation.
Discontinuation of an individual participant from the study  will be considered in the event of :
clinically  significant abnormalities in any  safet y tests as confirmed b y the investigator; or any 
medical or non- medical circumstances which, in the opinion of the investigator, pose a risk to 
the patien t by continuing in the study , or which do not allow the patient to adhere to protocol 
requirements . The Sponsor medical monitor should be notified within approximately  24 
hours when either of these circumstances occurs.
The stopping rule listed below will be employed during the conduct of this study . If th is
criteri onismet, the study may  be paused until the Sponsor has reviewed the totality  of data 
available. 
a. An individual participant reports a Serious Adverse Event considered related to the 
study  drug b y the investigator. Two (2) or more participants within a P art(at the same 
dose level) report Severe Non- serious Adverse Events considered related to the study  
drug b y the investigator.
If any of these criteria are met, subsequent doses of treatment for r emaining participants may  
be adjusted (maintained at the same level, decreased or halted) based upon joint agreement of 
the Sponsor and investigator.
6.6.2 Dizziness/Nausea Stopping Criteria
Dizziness
Previous investigations (MK -1942- 001, 002, 003) reported increases in the incidence and 
severit y of dizziness episodes with doses of MK -1942 ≥8-mg. These results suggest that the 
AE of dizziness may  occur over the dose range proposed for this study  and tha t the number 
CCI
087PVJ
PRODUCT: MK-1942  62
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
and severit y of dizziness episodes should be monitored as part of the dose escalation stopping 
criteria.  
The following parameters are used for determining whether to adjust dosing for an individual 
based on the presence of dizziness:
A susta ined sy mptom, defined as lasting ≥ 4hours in duration and;
A severit y of Grade 2 (“Moderate”) intensity of dizziness, defined as including:
Subject reports feeling a spinning or sway ing movement that is not relieved 
when supine; AND
Subject reports feelin g unsteady  or about to lose their balance upon walking
(postural dizziness); AND/OR
The Targeted Neurological Examination records that gait or extraocular 
movement sareimpaired.
If a participant reports sustained dizziness that, in the opinion of the investigator, is of 
moderate or greater severity  and is related to study drug administration, then the dose for that 
participant will not be escalated. Continued dosing of the individual at the same or a lower 
level may  be considered, or dosing may  be stop ped.
Nausea
Episodes of nausea were reported during studies MK -1942- 001 (see MK -1942 IB) and MK -
1942- 002 [Sec. 2.2.3]. These events were observed less frequentl y than those of dizziness 
and were mild to moderate in intensity . The results suggest that the A E of nausea may  occur 
over the dose range proposed for this study  and that the number of episodes and their severity  
should be monitored as part of the dose escalation stopping criteria.
The definition of Grade 2 (“Moderate”) severity  nausea includes signs and sy mptoms that 
interfere with activities of daily living but require no treatment or intervention. If participants 
show sustained (> 4hrs) phy sical signs and/or s ymptoms of nausea that, in the opinion of the 
investigator, are of moderate or greater se verity  and are related to study  drug administration, 
then the dose for that participant will not be escalated. Continued dosing at the same or a 
lower level may  be considered, or dosing for that individual may  stop. If considered 
necessary  by the investiga tor, supportive care may be provided until the signs/sy mptoms 
return to baseline.
Stopping Criteria
If >2 subjects meet the criteria defined above, there will be no dose escalation. 
Administration of study  treatment to all participants may continue at the same or lower dose, 
for a longer duration of administration (not to exceed the 28 -day limit), or may  be halted, 
with agreement of the investigator and Sponsor. 
087PVJ
PRODUCT: MK-1942  63
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
These rules are not meant to be comprehensive but to provide clear guidance for the 
adjustment or discontinuation of dosing. However, due to the uncertain nature of Phase 1 
trials, these rules should not be considered a substitute for clinical judgment. I f unforeseen 
events demonstrate that participants meet these stopping criteria, but clinical jud gment allows 
for continuance, then with the agreement of the Investigator and the Sponsor, and with the 
consent of the participant, dosing may  be continued. Conversel y, if the participant does not 
meet the criteria warranted by the stopping rules but clini cal judgment mandates that dosing 
be halted, then dosing of the participants may  be discontinued.
Participant Lost to Follow -up
Specific details regarding procedures to be performed at the time of withdrawal from the 
study , as well as specific details regarding withdrawal from future biomedical research, are 
outlined in Section 8.1.9. The procedures to be performed should a participant repeatedl y fail 
to return for scheduled visits and/or if the study  site is unable to contact the participant are 
outlin ed in Section 7.3. , Lost to Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
•The site must attempt to contact the part icipant and reschedule the missed visit. If 
the participant is contacted, the participant should be counseled on the importance 
of maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact with the
participant at each missed visit (eg, telephone calls and/or a certified letter to the 
participant’s last known mailing address or locally equivalent methods). These contact 
attempts should be documented in the participant’s medical record.
6.7 Interventi on After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
The emergency  unblinding call center will use the intervention allocation/randomization 
schedule for the study  to unblind participants and to un mask study  intervention identity  . The 
emergency  unblinding call center should only  be used in cases of emergency  (see Section 
8.1.10). The Sponsor will not provide random code/disclosure envelopes or lists with the 
clinical supplies.
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL
7.1 Discontinuation of Study Intervention
Discontinuation of study  intervention does not represent withdrawal from the study .
087PVJ
PRODUCT: MK-1942  64
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
As certain data on clinical events bey ond study  intervention discont inuation may  be 
important to the study , they  must be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study  intervention prior to completi on of the protocol -specified treatment 
period/vaccination regimen will still continue to participate in the stud y as specified in 
Section 1.3 and Section 8.1.9, or if available, a protocol clarification letter .
Participants may  discontinue study  interventi on at any  time for any  reason or be discontinued 
from the study  intervention at the discretion of the investigator should an y untoward effect 
occur. In addition, a participant may  be discontinued from study  intervention by  the 
investigator or the Sponsor i f study  intervention is inappropriate, the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation are provided in Sections 8.1.9 .
A participant must be discontinued from study intervention but continue to be monitored in 
the study  for an y of the following reasons:
•The participant or participant’s legall y acceptable representative requests to discontinue 
study  intervention.
•The participant’s treatm ent assignment has been unblinded by  the investigator, MSD 
subsidiary , or through the emergency  unblinding call center.
•The participant interrupts study  intervention administration for more than 2consecutive 
days or has 2cumulative missed doses.
•The participant has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•The participant has a confirmed positive serum pregnancy  test.
•The participant has a positive UDS at any  time during the course of the study .
For participants who are discontinued from study  intervention all applicable discontinuation 
activities will be performed according to Section 8.1.9, or if available, a protocol clarification 
letter.
7.2 Participant Withdrawal From the Study
A participant must be withdrawn from the study  if the participant or participant’s legall y 
acceptable representative withdraws consent from the study .
If a participant withdraws from the study , they  will no longer receive study  intervention or be 
followed at scheduled protocol visits.
087PVJ
PRODUCT: MK-1942  65
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Participants may  withdraw from the study  at an y time for an y reason. If a participant 
withdraws from the study, they  will no longer receive stu dy intervention or be followed at 
scheduled protocol visits.
A participant must be withdrawn from the study  if:
•The participant or participant’s legall y acceptable representative withdraws consent
from the study .
•Participant is lost to follow- up
Specific d etails regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific details regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.9. The procedures to be performed should a participant repea tedly fail 
to return for scheduled visits and/or if the study  site is unable to contact the participant are 
outlined in Section 7.3.
7.3 Lost t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
tocontact the participant, the following procedures are to be performed:
•The site must attempt to contact the participant and reschedule the missed visit. I f the 
participant is contacted, the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact with the participant 
at each missed visit (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact attempts should be 
documented in the participant’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
appropriatel y qualified (by education, training, and experience) staff. Delegation of study  
site personnel responsibiliti es will be docu mented in the I nvestigator Trial File Binder (or 
equivalent).
087PVJ
PRODUCT: MK-1942  66
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
•All study -related medica l decisions must be made by  an investigator who is a qualified 
physician .
•All screening evaluations must be completed and reviewed to confirm that potentia l 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
•Additional evaluations/testing may  be deemed necessary  by the investigator and or the 
Sponsor for reasons related to participant safet y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulations.
•Procedures conducted as part of a site generic screening (with an ERC/I RB approved site 
generic screening consent) on potential participants (eg, blood count, vital signs, ECG, 
etc.) and obtained before signing of stud y ICF may be utilized for screening or baseline 
purposes provided the procedures met the protoc ol specified criteria and were performed 
within the screening window defined in this protocol.
The maximum amount of blood collected from each participant over the duration of the study
will not exceed 500mL(Appendix 8).
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each pot ential participant or each participant’s legall y 
acceptable representative prior to participating in a clinical study or future biomedical 
research .If there are changes to the participant’s status during the stud y (eg, health or age of 
majority  requirements), the investigator or medically  qualified designee must ensure the 
appropriate consent is in place.
8.1.1.1 General Informed Consent
Consent must be docum ented by  the participant’s dated signature or b y the participant’s 
legally  acceptable representative’s dated signature on a consent form along with the dated 
signature of the person conducting the consent discussion.
087PVJ
PRODUCT: MK-1942  67
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the IRB/IEC’s approval/favorable opinion in advance of use. The 
participant or his/her legally  acceptable representative should be informed in a timely  manner 
if new information becomes available that may  be relevant to the participant’s willingness to 
continue participation in the study . The communication of this information will be provided 
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s dated signature or b y the participant’s legall y acceptable 
representative’s dated signature.
The participant or his/her legally  acceptable representative will be asked to sign consent at 
the point of initial radiographic disease progression.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The inform ed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or qualified designee will explain the future biomedical research consent to 
the participant, answer all his/her questions, and obtain written informed consent before 
performing an y procedure related to future biomedical research. A cop y of the informed 
consent will be given to the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator ,who is a qualified 
physician ,to ensure that the participant qualifies for the study .
8.1.3 Participant Identi fication Ca rd
All participants will be given a participant identification card identify ing them as participants 
in a research stud y. The card will contain study site contact information (including direct 
telephone numbers) to be used in the event of an eme rgency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
CCI
087PVJ
PRODUCT: MK-1942  68
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
the participant provides written informed consent. At the time of intervention randomization,
site personnel will add the t reatment /randomization number to the participant identification 
card.
The participant identification card also contains contact information for the emergency 
unblinding call center so that a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history  will be obtained by  the investigator or qualified designee.
8.1.5 Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qual ified designee will review prior medication use, including an y 
protocol -specified washout requirement, and record prior medication taken by  the participant 
within 4 weeks or 5 half -lives before the screening visit. An y medications necessary for 
keeping a c andidate stably  treated for an underl ying condition should be reviewed by  the PI 
for potential interference with/by  the study  medication  and brought 
to the attention of the Sponsor for mutual agreement on whether to enroll the candidate in the 
study  (Section 6.5).  Participants will be stably  maintained on donepezil ( ≥10-mg, ≤15-mg) 
for at least 1 month prior to enrollment.
8.1.5.2 Concomitant Medications
Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the participant 
during the stud y.Participants will be stably  maintained on donepezil ( ≥10-mg, ≤15-mg) for 
at least 1 month prior to enrollment.
8.1.6 Assignment of Screening Numb er
All consented participants will be given a unique screening nu mber that will be used to 
identify  the participant for all procedures that occur prior to randomization . Each participant 
will be assigned onl y 1 screening number. Screening numbers must not be re -used for 
different participants.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive an allocation number. 
The allocation number identifies the participant for all procedures occurring after treatment 
allocation. Once an allocation number is assigned to a participant, it can never be re -assigned 
to another participant.
A single participant cannot be assigned more than 1 allocation number.
CCI
087PVJ
PRODUCT: MK-1942  69
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
8.1.8 Study Intervention Administrati on
Study  intervention should begin on the day  of treatment allocation/randomization or as close 
as possible to the date on which the participant is allocated/assigned. All doses of study 
treatment (MK -1942/placebo) will be provided as dry  filled capsule and matching placebo.
These will be administered orall y with at least 240 mL  (not to exceed 500 mL ) of water upon 
completion of all pre -dose procedures for that day , with administration of study  medication 
witnessed by  the investigator and/or study staff. Subje cts will not be allowed access to food 
for 2 hours after both the morning and evening doses.
8.1.8.1 Timing of Dose Administration
The first oral doses of MK- 1942/placebo will be administered in the morning at 
approximately  the same time every  day. After all pre-dose procedures are completed on the 
morning of Day  1, either MK -1942 or placebo will be administered (Section 8.1.8), with the 
time of administration constituting Time “0”. All capsules will be distributed and consumed 
within 10 minutes of the recorde d administration time. Participants will remain resting in bed 
in a semi -recumbent position for approximately 2 hours after dosing. Participants may  
ambulate freel y after the 2 -hour VS and ECGs if no clinically significant changes are
observed.
Participants will receive the second dail y oral dose of MK -1942/placebo approximately  12 
hours after the time the first daily  dose was administered. A ll capsules will be administered 
within 10 minutes of the of the exact time when treatment is administered, andthat 
administration time recorded. On Day  21(28), only  the morning dose will be administered. 
Participants will remain resting in bed in a semi -recumbent position for approximately  2 
hours after dosing. Participants may ambulate freely after the 2 -hour VS and ECG measures 
if no clinically  significant changes are observed.
Donepezil will be administered in the mornings at approximately  the same time as 
MK-1942/placebo. If participants do not usually  take their Donepezil in the mornings, they  
should be instructed to start taking it in the morning starting on Day  -7. 
8.1.9 Discontinuation and Withdrawal
The investigator or study coordinator must notify the Sponsor when a participant has been 
discontinued/withdrawn from the study . If a participant discontinues for any reason at an y 
time during the course of the study , the participant may  be asked to return to the clinic (or be 
contacted) for a poststudy visit as per the number of day s described in Section 8.10.4) to have 
the applicable procedures conducted. However, the i nvestigator may  decide to perform the 
poststudy  procedures at the time of discontinuation or as soon as possible after 
discontinuation. I f the poststudy  visit occurs prior to the safet y follow -up time frame as 
specified in Section 8.4.1, the investigator s hould perform a follow -up telephone call at the 
end of the follow -up period (Section 8.4.1) to confirm if any  AEs have occurred since the 
poststudy  clinic visit. Any  AEs that are present at the time of discontinuation/withdrawal 
should be followed in accor dance with the safet y requirements outlined in Section 8.4.
087PVJ
PRODUCT: MK-1942  70
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
8.1.9.1 Withdrawal From Future Biomedical Resear ch
Participants may  withdraw their consent for future biomedical research. Participants may  
withdraw consent at an y time by  contacting the investigator for the main study . If medical 
records for the main study are still available, the investigator will contact the Sponsor using 
the designated mailbox (clinical.specimen.management@merck.com). Subsequently, the 
participant's consent for future biomedical resear ch will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. I t is the responsibility  of the 
investigator to inform the participant of completion of withdrawal. An y analy ses in progress 
at the time of request for withdrawal or alread y performed prior to the request being received 
by the Sponsor will continue to be used as part of the overall research study  data and results. 
No new analy ses would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
8.1.10 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the intervention used by  a participant and/or th e 
dosage administered, he/she will contact the emergency  unblinding call center by  telephone 
and make a request for emergency  unblinding. As requested b y the investigator or medically 
qualified designee, the emergency  unblinding call center will provide th e information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contacting the emergency  
unblinding call center to request unblinding of a participant’s intervention assignment, the 
investigator who is qualified physician should make reaso nable attempts to enter the intensit y 
grade of the AEs observed, the relation to study  drug, the reason thereof, etc., in the medical 
chart. If it is not possible to record this assessment in the chart prior to the unblinding, the 
unblinding should not be delay ed.
Ifunblinding has occurred, the circumstances around the unblinding (eg, date, reason, and 
person performing the unblinding) must be documented promptly , and the Sponsor Clinical 
Director notified as soon as possible.
Once an emergency  unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel may  be unblinded so that the appropriate follow -up medical care can be 
provided to the participant.
087PVJ
PRODUCT: MK-1942  71
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Participants whose treatment assignment has been unblinded by the investi gator or medicall y 
qualified designee and/or nonstudy  treating ph ysician must be discontinued from study  
intervention but should continue to be monitored in the study.
8.1.11 Domicili ng
Participants will report to the clinical research unit (CRU) on Day  -2 prior to the scheduled 
day of administration of the study  treatment or at the discretion of the investigator.
Participants may  be domiciled in the unit for -2 day s before dosing study  drug , for up to 28 
daysof treatment ,and with an additional three days of in-house, post-treatment follow up. 
Participants will be released from the CRU with instructions to return for the post -study  
examination, to be performed 14 day s after the last day  of dosing.
At the discretion of the investigator, participants may request to go home for day s 5 and 6 of 
each dose level .  At-home monitoring of AEs and treatment compliance will be conducted by 
daily  telephone calls from the CRU.  Participants should return to the CRU the evening of 
day 6 of each dose level in order to be read y for procedures conducted the following 
morning.
At the discretion of the investigator, participants may be requested to remain overnight in the 
CRU for longer than 30 day s. Participants may be permitted to leave the unit for emergency  
situations only  during the domiciling period at the discretion of the investigator after 
discussion with the Sponsor. The decision on how to continue monitor ingthe participant will 
be at the discretion of the investigator after discussion with the Sponsor.
8.1.12 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or effic acy parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
8.2 Efficacy/Immunogenicity Assessmen ts
There are no direct efficacy assessments in this study.
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood to be drawn over the course of the study ( from pre -study  
to post -study  visits), including approximate blood volumes drawn b y visit and by sample 
type per particip ant, can be found in Appendix 8.
Planned time points for all safety assessments are provided in the SoA.
087PVJ
PRODUCT: MK-1942  72
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
8.3.1 Physical Examinations
A complet e physical examination will be conducted by an investigator or medically  qualified 
designee (consistent with local requirements) as per institutional standard. Height and weight 
will also be measured and recorded.
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
Body Mass Index (BMI)
Body Mass Index equals a person's weight in kilograms divided by height in meters squared 
(BMI=kg/m2). Bod y Mass I ndex will be rounded to the nearest whole number according to 
the standard convention of 0.1 -0.4 round down and 0.5 -0.9 round up.
Body weight and height will be obtained with the participant’s shoes off and jacket or coat 
removed.
8.3.2 Vital Signs
•Oral, ty mpanic, or temporal body  temperature, pulse rate, respiratory  rate, and blood 
pressure will be assessed.
•Blood pressure and pulse measurements will be assessed in the semi -recumbent and/or 
standing position with a completely automated device. Manual techniques will be used 
only if an automated device is not available.
•Blood pressure and pulse measurements should be preceded b y at least 10minutes of rest 
bythe participant in a quiet setting without distractions.
8.3.2.1 Resting Vital Signs
Vital Sign Measurements (Heart Rate and Blood Pressure)
Participants should be resting in a semi -recumbent position for at least 10 minutes prior to 
having VS measurements obtained. Semi -recumbent VS will include HR and BP. The correct 
size of the BP cuff and the correct positioning on the participants' arm is essential to increase 
the accuracy  of BP measurements.
The pre -dose (baseline) HR and BP will be triplicate measurements, obtained at least 1 -2 
minutes apart within 3 hours before dosing MK -1942 on Day  1. The mean of these 
measurements will be used as the baseline to calculate change from b aseline for safet y 
evaluations (and for rechecks, if needed). On all other day s indicated in the SoA (See Section 
1.3) pre -dose HR and BP will be single measurements. Post-dose VS measurements will be 
single measurements unless there is an out -of-range rea
ding. In this case, at least three 
measures of VS (either resting or orthostatic HR, BP) will be taken within a 15 -minute 
period, or until readings fall into normal range .
087PVJ
PRODUCT: MK-1942  73
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Participants will continue to rest semi -recumbent from dosing until 2 hours post -dose,except 
to stand for the measurement of orthostatic VS or other study -related procedures.
Body Temperature
Body temperature will be measured. The same method must be used for all measurements for 
each individual participant and should be the same for all participants.
8.3.2.2 Orthostatic Vital Signs
Orthostatic VS (HR and BP) will be obtained. Participants should be semi -recumbent for at 
least 10 minutes and then stand upright for 2 minutes prior to measurement of orthostatic VS.
8.3.3 Electrocardiograms
Special care must be taken for proper lead placement by  qualified personnel. Skin should be 
clean and dry  prior to lead placement. Participants may  need to be shaved to ensure proper 
lead placement. Female participants may  need to remove interfering garments.
Participants should be resting in the semi -recumbent for at least 10 minutes prior to each 
ECG measurement.
The correction formula to be used for QTc is Fridericia.
As repeat ECGs are required in this study , the clinical site will decide whether to leave the 
electr odes in place or mark the position of the electrodes for subsequent ECGs. To mark the 
position of the electrodes, 12- lead electrode sites will be marked on the skin of each 
participant with an ECG skin marker pen to ensure reproducible electrode placement.
All ECGs will be taken in triplicate at least 1- 2 minutes apart at the times/dates indicated in 
the SoA (See Section 1.3). The mean of these measurements will be used to calculate the 
change from baseline for safet y evaluations and for rechecks, if needed . Pre-dose ECGs will 
be obtained within 3 hours before dosing MK -1942/placebo.
During each treatment period, if a participant demonstrates an increase in mean QTc interval
≥ 60 msec compared to the mean pre -dose baseline measurement, the participant will b e 
monitored by  recording 12 -lead ECGs in triplicate every  15 minutes for at least 1 hour, or 
until the QTc is within 60 msec of baseline. If prolongation of the QTc interval ≥60 msec 
persists, a consultation with a study cardiologist may be appropriate and the Sponsor should 
be notified.
If the QTc interval is  500 msec, the Sponsor should be notified, and the ECGs should be 
reviewed b y a cardiologist. The ECG reader will be blinded to treatment, treatment period 
and timepoint. The participant may  be teleme try-monitored until the QTc is < 500 msec or 
should be considered for transfer to a location where closer monitoring and definitive care 
(eg, a cardiac or intensive care unit) is available.
087PVJ
PRODUCT: MK-1942  74
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
If the participant has unstable hemod ynamics or if any clinically  significant dy srhythmias are 
noted, the participant should be immediately  transferred to an acute care setting for definitive 
therap y.
A study  cardiologist will be consulted b y the PIas needed to review ECG tracings with 
abnormalities.
8.3.4 Neurological Exams
The full neurological exam monitors aspects of mental status, cranial nerve function, motor 
system function, reflexes, coordination and gait and sensory  function (Appendix 11) and will 
be administered at screening and the post- trial exam. The targeted neur ological exam 
contains Modules 1, 2 and 5 of the general examination, focusing on arousal, cranial nerve 
function, and gait.
8.3.5 Mini -Mental State Examination (MMSE -2)
The MMSE- 2 will be administered to the participant in paper form ,scored and recorded b y 
theprincipal investigator or trained designee according to the instructions in the operations 
manual. 
8.3.6 WAIS -R Digit Symbol Substitution Test (DSST)
The DSST will be administered to the participant in paper form and scored and recorded b y 
the principal invest igator or trained designee according to the instructions in the operations 
manual. 
8.3.7 Clinical Safety Laboratory Assessments
Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The invest igator or medically  qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record an y clinically 
relevant changes occurring during the stud y in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically  significant abnormal 
laboratory  findings are those which are not associated with the underl ying disease, unless 
judged b y the investigator to be more severe than expected for the participant's condition.
•All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA .
•If laboratory  values from nonprotocol -specified laboratory  assessments performed at the 
institution’s local labo
ratory  require a change in study  participant management or are 
considered clinically  significant by  the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
087PVJ
PRODUCT: MK-1942  75
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
•For an y laboratory  tests with va lues considered clinically  significantl y abnormal during 
participation in the study  or within 14days after the last dose of stud y intervention , every  
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by  the investigator .
8.3.8 Suicidal Ideation and Behavior Monitoring
8.3.8.1 Clinical Assessments for Suicidal Ideation and Behavior Monitoring
Suicidal ideation and behavior will be prospectively assessed during this study using the C -
SSRS. The C -SSRS should be administered by trained raters at the time points indicated in 
the SoA. I n addition, C -SSRS will be administered at an y unscheduled visit where safet y 
assessments are performed. The C -SSRS will not be routinely  admin istered at visits with a 
sole purpose of PK sampling and/or witnessed study intervention administration. Site staff 
should review the contents of the C -SSRS for completeness. If the C -SSRS is administered 
by someone other than the investigator, consider pr oviding the completed C -SSRS to the 
investigator for review, prior to their assessment of the participant and to further inform their 
evaluation. The C -SSRS is not explicit about whether the participant specifically  has ideation 
at the time of screening. I f a participant reports a prior history of ideation/behavior at 
screening, the assessor should also inquire and document if this is also present at the time of 
the screening visit.
Participants who at an y time during this study report suicidal ideation or behavior that is 
considered an AE, either between visits or during visit interviews, must be assessed b y the 
investigator. Participants who report suicidal ideation with intent, with or without a plan or 
method (ie, a positive response to items 4 or 5 in the assessment of suicidal ideation on the 
C
-SSRS) or suicidal behavior must be evaluated that day  by a ps ychiatrist or other trained 
mental health professional who is a licensed ps ychologist, social worker, or mental health 
nurse practitioner (or comparabl e professional qualification in countries outside the United 
States). Only  participants whose suicidal ideation is passive, who expressly  deny  any intent 
to act, and who, after evaluation, are not judged to be at serious risk for self -harm during the 
study may continue in the study ; other participants must be discontinued from study  
participation and receive appropriate clinical follow -up care to ensure their safet y. In 
addition, all AEs of suicidal ideation or behavior must be recorded as an ECI  (See Secti on 
8.4.7). Sites are to designate which health care professionals are to be responsible for acute 
care on -site and to specify  referral center(s) to be used for further evaluation.
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  the participant 
(or, when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized 
representative).
087PVJ
PRODUCT: MK-1942  76
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
The investigator and an y designees are responsible for detecting , documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety  
events for outcome according to Section 8.4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE , SAE ,and Other Reportable 
Safety Event Information
AEs, SAEs, and other reportable safety  events that occur after the consent for m is signed but 
before intervention allocation/randomization , must be reported b y the investigator for 
randomized participant s only  if the event is the result of a protocol -specified intervention, 
including but not limited to washout or discontinuation of usual therap y, diet, placebo 
treatment, or a procedure.
From the time of intervention allocation/randomization through 14 day s following cessation 
of intervention, all AEs, SAEs and other reportable safet y events must be reported b y the 
investigator.
Additionally , any SAE brought to the attention of an investigator an y time outside of the time 
period specified in the previous pa ragraph also must be reported immediately  to the Sponsor 
if the event is considered related to study intervention .
Investigators are not obligated to activel y seek AE sor SAEs or other reportable safety  events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 9 .      
087PVJ
PRODUCT: MK-1942  77
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Table 9 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of EventReporting Time 
Period:
Consent to 
Randomizat ion/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
specified Follow -
up PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame to 
Report Event and 
Follow -up 
Inform ation to 
Sponsor:
Nonserious 
Adverse Event 
(NSAE) Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
(Follow  ongoing to 
outcome)Within 24 hours of 
learning of event
Pregn ancy/Lactati
on ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin 24 hours of 
learning of event
Event of Clinical 
Interest (require 
regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-potential drug -
induced liver 
injury (DILI)
-require 
regulatory 
reportingNot required Within 24 hours of 
learning of event
Event of Clinical 
Interest (do not 
require regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-non-DILI ECIs 
and those not 
requiring 
regulatory 
reportingNot required Within 5 calendar 
days of learning of 
event
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 calendar 
days of learning of 
event
Overdose Report if:
-receiving 
placebo run -in or 
other run -in 
medication Report all Not required Within 24 hours of 
learning of event
087PVJ
PRODUCT: MK-1942  78
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and nonleading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence .
8.4.3 Follow -up of AE, SAE ,and Other Reportab le Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safet y events ,
including pregnancy  and exposure during breas tfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every  attempt to fol low all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safet y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
Sponsor will comply  with country -specific regulatory  requirements and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and Sponsor policy  and forwarded to inve stigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if approp riate according to local requirements.
8.4.5 Pregnancy and Exposure During Breastfeeding
This section is not applicable.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Disease related events and or disease related outcomes not qualify ing as AEs or SAEs are not 
applicable to this study .
8.4.7 Events of Clinical Interest
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
087PVJ
PRODUCT: MK-1942  79
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Events of clinical interest for this study include: 
1.An overdose of Sponsor 's product, as defined in Section 8.5.
2.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same t ime, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by  way  of protocol- specified laboratory  
testing or unscheduled laboratory  testing.*
*Note: These criteria are based upon available regulatory guidance docu ments. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that must trigger 
an additional evaluation for an underl ying etiology. The study  site guidance for 
assessment and follow up of these criteria can be found in the Investigator Study  File 
Binder (or equivalent).
It may  also be appropriate to conduct additional evaluation for an underl ying etiology  in 
the setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and 
alkaline phosphatase that do not meet the criteria noted above. In these cases, the decision 
to proceed with additional evaluation will be made through consultation between the 
study  investigators and the Sponsor Clinical Director. However, abnormalities of liver 
blood tests that do not meet the criteria noted above are not ECIs for this study .
3.Suicidal ideation and/or suicidal behavior. A supplemental document will be provided 
that contains guidance for additional information to be collected and reported for these 
events (Appendix 12).
8.5 Treat ment of Overdose
For purposes of this study, an overdose will be defined as an y dose of an y drug administered 
as part of the trial exceeding the dose prescribed by the protocol. It is up to the investigator or 
the reporting ph ysician to decide whether a do se is to be considered an overdose, in 
consultation with the Sponsor.
8.6 Pharmacokinetics
The decision as to which plasma samples collected will be assayed for evaluation of PK/PD 
will be collaborativel y determined by the Sponsor (eg, samples at lower doses may not be 
assay ed if samples at higher doses reveal undetectable drug concentrations). If indicated, 
these samples may  also be assay ed and/or pooled for assay  in an exploratory manner for 
metabolites and/or additional pharmacod ynamic markers.
8.6.1 Bloo d Collection for Plasma MK -1942
Sample collection, storage, and shipment instructions for plasma samples will be provided in 
the operations manual .
087PVJ
PRODUCT: MK-1942  80
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
8.7 Pharmacodynamics
PD parameters will not be evaluated in this study .
8.8 Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from all participants as 
specified in the SoA: 
Blood for Genetic Anal ysis.
8.8.1 Planned Genetic Analy sis Sample Co llection
The p lanned genetic a nalysis sample should be drawn for planned analy sis of the association 
between genetic variants in DNA and drug response. This sample will not be collected at the 
site if there is either a local law or regulation prohibiting collection, or if the I RB/IEC does 
not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored for future biomedical researc h if the participant signs 
the future biomedical r esearch consent. If the planned genetic analysis is not approved, but 
future biomedical r esearch is approved and consent is given, this sample will b e collected for 
the purpose of future biomedical r esearch.
Sample collection, storage, and shipment instruct ion for planned genetic analysis samples 
will be provided in the operations/laboratory manual.
8.9 Future Biomedical Research Sample Collection
If the participant signs the future biomedical research consent, the following specimens will 
be obtained as part of f uture biomedical research:
•Leftover main stud y plasma from MK -1942 assay will be stored for future research
•Leftover DNA for future research
8.10 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details areprovided 
inSection 8.
8.10.1 Screening
Within approximately  5 weeks prior to intervention allocation/randomization, potential 
participants will be evaluated to determine that they fulfill the entry requirements as set forth 
in Section 5.
Participants may  be res creened after consultation with the Sponsor. Rescreening should be 
conducted if more than 35 day s have elapsed between the participant’s initial screening and 
087PVJ
PRODUCT: MK-1942  81
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
planned randomization. Rescreening should include all screening procedures listed in the 
SoA, inc luding consent review.  
Rescreen procedures cannot be 
conducted the day  prior to intervention allocation/randomization if there are Day -1 
procedures planned per protocol.
8.10.2 Treatment Period Visit
Refer to the SoA (Section 1.3) and Administrative and General Procedures (Section 8.1).
8.10.3 Discontinued Participants Continuing to be Monitored in the Study
At any  point if a participant discontinues from treatment but continues to be monitored in the 
study , allof stud y procedures specified in the SoA may be completed at the discretion of the 
investigator and with Sponsor agreement. The subset of study procedures completed will be 
communicated in a PC L.
8.10.4 Posts tudy
Participants will be required to return to clinic approximately  14 day s after the last dose of 
study  intervention for the poststudy  visit. If the post study  visit occurs less than 14 day s after 
the last dose of study  intervention, a subsequent follow -up telephone call should be made at 
14 day s post the last dose of study  intervention to determine if an y AEs have occurred since 
the post study  clinic visit.
8.10.5 Critical Procedures Based on Study Objectives: Timing of Procedure
For this study , taking the blood sample for MK -1942 is the critical procedure.
At any  post -dose time point, the blood sample for MK -1942 needs to be collected as close to 
the exact time point as possible. All other procedures should be completed as close to the 
prescribed/schedule d time as possible. Study  procedures can be performed prior or after the 
prescribed/scheduled time.
The order of priorit y can be changed during the study  with joint agreement of the investigator 
and the Sponsor Clinical Director.
Any nonscheduled procedure s required for urgent evaluation of safet y concerns take 
precedence over all routine scheduled procedures.
The following variance in procedure collection times will be permitted.
•PK Collection, as outlined in Table 10.
CCI
087PVJ
PRODUCT: MK-1942  82
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Table 10 Pharmacokinetic Sample (Blood) Collection Windows
PK Collection PK Collection Window
0 -<1 hr 5 min
1 -<24 hr 15 min
24-<48hr 1 hr
48-72hr 2 hr
•Predose standard safet y evaluations: 
oVitalsigns within 3 hrs prior to dosing
oECGs within 1 hour prior to dosing
oLaboratory  safet y tests and physical exam within 24 hrs prior to dosing
•Postdose standard safet y evaluations : vital signs, laboratory  safet y tests, targeted
neurological exam, phy sical exam, and C-SSRS 
a.<24 hr postdose :may be obtained within 30 minutes before and 1 hr after the 
stated monitoring time.
b.24 hr 
-<48 hr postdose :may be obtained within 4hr of the stated monitoring 
time.
Post-dose ECG evaluations
o<24 hours post -dose:should be taken within 15 minutes of stated recording time.
o24 hours post -dose:should be taken within 1 hour of stated recording time.
Study  drug administration: ±30mins of stated administration period (AM, PM) and ± 30 
minutes of previous day ’s administration times for a given participant.
8.10.6 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase 1 assessment of MK- 1942 in humans, and the PK, PD, and safet y profiles of 
the compound is still being elucidated. This protocol is written with some flexibility  to 
accommodate the inherent dy namic nature of Phase 1 clinical studies. Modifications to the 
dose, dosing regimen, and/or clinical or laboratory procedures currentl y outlined may  be 
required to achieve the scientific goals of the stud y objectives and/or to ensure appropriate 
safet y monitoring of the study participants.
As such, some alterations from the currentl y outlined dose and/or dosing regimen may  be 
permitted based on newly available data, but the maximum daily  dose may  not exceed those 
currentl y outlined in the protocol.
087PVJ
PRODUCT: MK-1942  83
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
•Repeat of or decrease in the dose of the stud y intervention administered in any
given period/panel
•Interchange of doses between panels
oEntire period(s) or panel(s) may  beomitted
oDecrease in the duration (eg, number of day s) of study  intervention administration
oAdjustment of the dosing interval (eg, divided doses [BID to QD, QD to BID, or
vice versa])
oInstructions to take study intervention with or without food or drink may  also be
modified based on newl y available data
oModification of the PK sample processing and shipping details based on newly
available data
The PK sampling scheme currently outlined in the protocol may  be modified during the study  
based on newl y available PK data (eg, to obtain data closer to the time of peak plasma 
concentrations). If indicated, these collected samples may also be assayed in an exploratory 
manner for metabolites.
Up to additional 50 mL  of blood may  be drawn for safet y and/or P Kanalyses. The total 
blood volume withdrawn from an y single participant will not exceed the maximum allowable 
volume during his/her participation in the entire study (Section 8).
The timing of pro cedures for assessment of safety procedures (eg, VS, ECG, safety 
laboratory  tests, etc.) may  be modified during the study  based on newl y available data. 
Additional laboratory  safety  tests may  be added to blood samples previously  drawn to obtain 
additional safet y information. These changes will not increase the number of study 
procedures for a given participant during his/her participation in the entire study.
It is understood that the current stud y ma y emplo y some or none of the alterations described 
above. Any alteration made to this protocol to meet the study objectives must be detailed b y 
the Sponsor in a letter to the Study  file and forwarded to the investigator for retention. The 
letter may  be forwarded to the I RB/IEC at the discretion of the investigat or.
9 STATISTICAL ANALYSIS PLAN
This section contains a summary  of the statistical anal yses for this trial. Full detail is in the 
Statistical Methods (Section 9.6).
087PVJ
PRODUCT: MK-1942  84
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
9.1 Statistical Analysis Plan Summary
Safety
Summary  statistics and plots will be generated for raw laboratory  safet y tests, ECGs, and/or 
vital signs as well as for change from baseline, as deemed clinicall y appropriate. Depending 
on the safet y parameter, the difference from baseline will either be computed on the original 
scale (raw change from base line) or on the log scale and back -transformed for reporting 
(percent change from baseline).
Frequency  and severity  of subjective reports of AEs over the dosing period will be closely  
monitored and reported. The counts and frequency of AEs will be summariz ed by  treatment.  
In addition, posterior probabilities (PP) of the incidence of dizziness, nausea, emesis after co-
administration of MK -1942 and donepezil to AD patients that are less than a target rate will 
be provided.  Such analyses may also be provided for other AEs identified during the stud y. 
The target rate is determined from the incidence of an AE associated with MK -1942 alone
from MK -1942 P004, and the maximum tolerable increase in the incidence of an AE.  For 
example, if the true AE rate of MK -1942 alone is 40% and the maximum tolerable increase 
in AE incidence associated with MK -1942 + donepezil compared to MK -1942 alone is 20%, 
the target rate would be 60%. A posterior probability  greater than 60% will be considered as 
tolerable. 
Responses to the C -SSRS will be tabulated and the individual score > 0 will be listed. The 
difference from pre -treatment baseline values will also be determined.
Pharmacokinetics
Model -based PK Summary
Evaluat ion of the effects of donepezil on the PK of MK -1942 in AD patients
At each dose level, individual values of the plasma Cmax of MK -1942 on the last day  of a 
titrated treatment regimen after co-administ ration of MK -1942 with donepezil to AD 
patients , as well as the Cmax of MK -1942 after administration of MK -1942 alone to HEV in 
MK-1942- 004 will be natural log transformed and anal yzed in an ANOVA model. The 
model contains one factor for treatment (MK -1942 alone in HEV, MK-1942+donepezil in 
AD patients). 
Ninety  percen t (90%) CIs will be constructed for GMRs (MK-1942 + donepezil in AD 
patients/ MK -1942 alone in HEV) from the model after back- transformation. The hy pothesis 
that t he plasma Cmax of MK -1942 determined on the last day of a titrated treatment regimen 
(Day 21 [28]) when co -administe red with donepezil to AD patients is similar to the Cmax 
obtained following administration of MK -1942 alone to HEV (MK-1942 -004) will be 
supported if the 90% CI for the true GMR (MK -1942 + donepezil in AD / MK -1942 alone in 
HEV) is contained within the interval (0. 5, 2.0).   Ninety -five percent (95%) CI s for the least 
squares means b y treatment will be constructed on the natural log scale and will reference a t -
distribution. Exponentiating the least square means and the lower an d upper limits of these 
087PVJ
PRODUCT: MK-1942  85
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
confidence intervals will yield estimates for the population geometric means and confidence 
intervals about the geometric means on the original scale. Similar anal yses will be conducted 
with MK -1942 AUC0 -12and Ctrough. 
Evaluat ion ofthe effects of MK -1942 on the PK of donepezil in AD patients
Separatel y for each PK parameter, i ndividual AUC0 -24andCmax of donepezil after co -
administration of MK -1942 and donepezil ,or donepezil alone (Day  -1) will be natural log 
transformed and ana lyzed in linear mixed effect model. The model contains fixed effect for 
treatment (MK -1942 and donepezil, donepezil alone )and random effect for subject . Ninety -
five percent (95%) CIs for the least squares means by treatment will be constructed on the 
natural log scale and will reference a t -distribution. Ninety  percent (90%) CIswill be 
constructed for the true GMRs (MK- 1942 + donepezil / donepezil alone ) from the model
after back- transformation.
Power
PK:
The estimate dpooled, between -subject standard deviations on a log scale for MK- 1942 
Cmax on the last day  of dosing following administration of 3 -mg to 20- mg BID doses of 
MK-1942 for 5 to 10 days to healthy  adults in MK -1942- 002 is 0.225. Assuming the standard 
deviation is 30% higher in AD patients than HEV (ie,the between- subject standard deviation 
on a log scale for Cmax is 0.29 in AD patients ), if the true GMR (MK- 1942+donepezil in AD 
patients/MK -1942 alone in HEV) is 1.00, with 18 AD patients receiving MK -1942 and 
donepezil and 6 HEV receiving MK- 1942 alone in MK -1942- 004, there is a 99% probability  
that the 90% CI  of the GMR will fall within the interval of (0.5, 2.0).   
Safety :
With 18AD patients receiving MK -1942 + donepezil and a target rate of 80%, if the tru e AE 
rate following administration of MK -1942 + donepezil in AD patients is 60%, there is a 
probability  of 97% that co -administration of MK -1942 with donepezil is considered safe and 
tolerable.
9.2 Responsibility for Analyses
The statistical anal ysis of the d ata obtained from this study  will be conducted by, or under the 
direct auspices of, the Early Clinical Development Statistics Department in collaboration 
with the Quantitative Pharmacology  and Pharmacometrics Department and Translational 
Pharmacology  Depar tment of the Sponsor.
Ifchanges are made to the statistical anal ysis plan as outline below after the study  has begun,
these deviations to the plan will be listed, along with an explanation as to why they occurred, 
in the Clinical Study  Report.
087PVJ
PRODUCT: MK-1942  86
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
9.3 Hypotheses/Estimation
Hypotheses
The plasma Cmax of MK -1942 determined on the last day  of a titrated treatment 
regimen ( Day 21 [28]) when co -administ ered with donepezil to AD patients is similar 
to the Cmax obtained following administration of MK -1942 alo ne to HEV in MK-
1942- 004. That is, the true GMR (MK -1942 + donepezil in AD / MK -1942 alone in 
HEV) is contained within the interval (0. 5, 2.0).
Estimations
The GMRs of plasma PK parameters (AUC0- 24andCmax) for those treated with 
MK-1942+ donepezil versus donepezil alone in AD patients will be estimated. 
9.4 Analysis Endpoints
Primary  Endpoints
1.Safety : AEs, vital signs, electrocardiograms, clinical chemistry , hematology , 
urinaly sis, targeted neurological exams, Columbia suicide severit y rating
scale.
Baseline is defined as the pre -dose measurement at Day  1.
Secondary  Endpoints
1.Pharmacokinetics: the plasma PK parameters of MK-1942 after administration of 
MK-1942 + donepezil -Cmax, Tmax, Ctrough, AUC0 -12, AUC0 -24 (day s 21 
and 28), and CL ss/F(days 21 and 28) , Vzss/F(days 21 and 28) , apparent terminal 
t1/2 (Day last –21 or 28 only ).
2.Pharmacokinetics: the plasma PK parameters of donepezil after administration of 
donepezil alone and donepezil + MK -1942 (Day s -1, 21, and 28) -Cmax, Tmax, 
and AUC0 -24.
Expl oratory  Endpoints:
1.MMSE -2 and DSST scores obtained at baseline (screening) and from the last 
day of dosing .
2.12-lead ECG parameters
9.5 Analysis Populations
The following populations are defined for the analysis and reporting of data. All participants 
will be reported, and their data analy zed, according to the treatment(s) they actuall y received.
All Subjects as Treated (ASasT): The All Subjects as Treated Population consists of all 
participants who received at least one dose of treatment. This population will be used for 
assessments of safety  and tolerability .
087PVJ
PRODUCT: MK-1942  87
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Per-Protocol (PP): The Per -Protocol Population consists of the set of data generated b y the 
subset of participants who comply  with the protocol sufficiently  to ensure that these data will 
be likely  to exh ibit the effects of treatment, according to the underl ying scientific model.
Compliance covers such considerations as exposure to treatment, availability of 
measurements and absence of important protocol deviations. I mportant protocol deviations 
will be identified to the extent possible prior to unblinding by individuals responsible for data 
collection/compliance, and its analysis and interpretation. An y participants or data values 
excluded from anal ysis will be identified, along with their reason for exclu sion, in the CSR. 
At the end of the stud y, all participants who are compliant with the study  procedure as 
aforementioned and have available data from at least one dose level will be included in the 
Per-Protocol dataset. This population will be used for the PK anal yses.
9.6 Statistical Methods
9.6.1 Safety
Summary  statistics and plots will be generated for raw laboratory  safet y tests, ECGs, and/or 
vital signs as well as for change from baseline, as deemed clinicall y appropriate. Depending 
on the safet y parameter, the difference from baseline will either be computed on the original 
scale (raw change from baseline) or on the log scale and back -transformed for reporting 
(percent change from baseline).
The f requency  and severity  of subjective reports of AEs over the dosin g period will be 
closely  monitored and reported. The counts and frequency  of AEs will be summarized by  
treatment.  In addition, posterior probabilities (PP) of the incidence of dizziness, nausea, 
emesis after co- administration of MK -1942 and donepezil to AD patients that are less than a 
target rate willbe provided.  Such anal yses may  also be provided for other AEs identified 
during the stud y. The target rate is determined from the incidence of an AE associated with 
MK-1942 alone from MK -1942 P004, and the maximum tolerable increase in the incidence 
of an AE.  For example, if the true AE rate of MK -1942 alone is 40% and the maximum 
tolerable increase in AE incidence associated with MK -1942 + donepezil compared to MK -
1942 alone is 20%, the target rate would be 60%. A posterior probabilit y greater than 60% 
will be considered as tolerable. 
Responses to the C -SSRS will be tabulated and the individual score > 0 will be listed. The 
difference from pre -treatment baseline values will also be determined.
9.6.2 Pharmacokine tics
Model -based PK Summary
Evaluat ion of the effects of donepezil on the PK of MK -1942 in AD patients
At each dose level, individual values of the plasma Cmax of MK -1942 on the last day  of a 
titrated treatment regimen after co-administ ration with donepezil to AD patients, as well as 
the Cmax of MK -1942 after administration of MK -1942 alone to HEV in MK -1942- 004 will 
087PVJ
PRODUCT: MK-1942  88
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
be natural log transformed and anal yzed in an ANOVA model. The model contains one 
factor for treatment (MK -1942 alone in HEV, MK-1942+donepezil in AD patients). 
Ninety  percent (90%) CIswill be constructed for GMRs (MK-1942 + donepezil in AD 
patients/ MK -1942 alone in HEV ) from the model after back- transformation. The hy pothesis 
that t he plasma Cmax of MK -1942 determined on the la st day  of a titrated treatment regimen 
(Day 21 [28]) when co -administe red with donepezil to AD patients is similar to the Cmax 
obtained following administration of MK -1942 alone to HEV (MK-1942 -004) will be 
supported if the 90% CI for the true GMR (MK -1942 + donepezil in AD / MK -1942 alone in 
HEV) is contained within the interval (0. 5, 2.0).   Ninety -five percent (95%) CI s for the least 
squares means b y treatment will be constructed on the natural log scale and will reference a t -
distribution. Exponentiating the least square means and the lower and upper limits of these 
confidence intervals will yield estimates for the population geometric means and confidence 
intervals about the geometric means on the original scale. Similar anal yses will be conducted 
with M K-1942 AUC0 -12 and Ctrough. 
Evaluat ion of the effects of MK -1942 on the PK of donepezil in AD patients
Separatel y for each PK parameter, i ndividual AUC0 -24andCmax of donepezil when co-
administ ered with MK-1942 or alone (Day  -1) will be natural log transformed and analyzed 
in a linear mixed effects model. The model contains fixed effect for treatment (MK -1942 and 
donepezil, donepezil alone )and random effect for subject . Ninety -five percent (95%) CIs for 
the least squares means by treatment will be constructed on the natural log scale and will 
reference a t -distribution. Ninety  percent (90%) CIswill be constructed for the true GMRs 
(MK- 1942 + donepezil / donepezil alone ) from the model after back -transformation.
Descriptive Statis tics
Individual values will be listed for each PK parameter b y dose level , and the following (non-
model -based) descriptive statistics will be provided, if appropriate: N (number of participants 
with non- missing data), arithmetic mean, standard deviation, a rithmetic percent CV 
(calculated as 100 x standard deviation/arithmetic mean), median, minimum, maximum, 
geometric mean, and geometric percent CV (calculated as 100 x sqrt(exp(s2) - 1), where s2 is 
the observed variance on the natural log -scale).
Explorator y Analysis
MMSE -2 scores
In order to evaluate the change in cognitive function of AD patients, descriptive summary  
statistics of the values and the change from baseline values will provided for the MMSE -2 
scores obtained at baseline (screening) andfrom the last day  of dosing .
WAIS-R DSST scores
Inorder to evaluate the change in cognitive function of AD patients, descriptive summary  
statistics of the values and the change from baseline values will provided for the DSST 
scores obtained at baseline ( Day -1), Day  14, and from the last day  of dosing (Day  21 [28])
087PVJ
PRODUCT: MK-1942  89
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Concentration- QTc
The average of the triplicate measurements at an y time point will be calculated prior to an y 
further anal ysis. Fridericia’s correction to QT ( QTcF = QT / RR1/3) will be made in order to 
correct for heart rate. The appropriateness of the correction factor (ie, 1/3) will be assessed 
via a linear mixed effects model with QTcF as the response variable and RR interval as a 
covariate and subject as a random effect, using data from the placebo treatment and the 
predose measurements of the active treatments. A slope estimate close to zero would indicate 
that Fridericia's correction provides an adequate correction to the original QT data; 
otherwise, an appropriate transformation on RR w ill be further explored.
The predose value on Day  1 will serve as baseline for calculating individual change from 
baseline at each time point. Observed plasma concentrations and observed QTcF change 
from baseline will be used to investigate the relationship between QTcF and plasma MK -
1942 concentrations (placebo data will also be used in this assessment, with the plasma 
concentration of MK -1942 set to 0). Scatter plots of QTcF change from baseline versus 
corresponding time -matched MK -1942 concentration will be provided.
The QTcF change from baseline will be further evaluated using a linear mixed effects model 
with fixed effects for treatment (MK -1942, placebo) ,time point ,continuous effects for QTcF 
baseline ,plasma concentration. A double compound sy mmetr y covariance structure will be 
assumed. The highest ‘safe’ drug concentration (C_safe), defined as the highest drug 
concentration whose upper limit of the two -sided 90% confidence interval (equivalent to a 
one-sided upper 95% confidence limit) of ΔΔQTcF (p lacebo -baseline -adjusted) less than 10 
milliseconds (ms), will be reported. An estimate of the expected mean effect and 90% 
confidence interval of ΔΔQTcF will also be computed at the observed geometric mean Cmax 
for each MK- 1942 dose of interest.
Additio nal modeling of the concentration and QTc data from this study may be conducted 
later as part of a broader evaluation of MK -1942's QTc prolongation potential. I n that case, a 
separate Modeling Anal ysis Plan will be written prior to anal ysis.
9.6.3 General
For al l analy ses, data will be examined for departures from the assumptions of the statistical 
model(s) as appropriate; eg, heteroscedasticit y, non -normality  of the error terms.
Distribution
-free methods may  be used if a serious departure from the assumptions of the 
models(s) is observed, or suitable data transformations may be applied.
9.7 Interim Analyses
No interim anal ysis is scheduled .
9.8 Multiplicity
Since there is no primary hypothesis, no adjustments for multiplicity  are needed.
087PVJ
PRODUCT: MK-1942  90
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
9.9 Sample Size and Power Calculations
PK:
The estimate dpooled, between -subject standard deviations on log scale for MK -1942 Cmax 
on the last day  of dosing following administration of  BID doses of MK -1942 
for 5 to 10 day s in healthy subjects in MK -1942 -002 is 0.225. Assuming the standard 
deviation is 30% higher in AD patients than HEV, i.e. the between- subject standard deviation 
on a log scale for Cmax is 0.29 in AD patients, if the true GMR (MK -1942+donepezil in AD 
patients/MK -1942 alone in HEV) is 1.00, with 18 AD patients receiving MK -1942 and 
donepezil and 6 HEV receiving MK- 1942 alone in MK -1942- 004, there is 99% probability  
that the 90% CI  of the GMR will fall completely  within the interval of (0.5, 2.0).   
Safety :
With 18AD patients receiving MK -1942 + donepe ziland a target rate of 80% , if the true AE 
rate following administration of MK -1942 + donepezil in AD patients is 60%,there is a 
probability  of 97% that the coadministration of MK -1942 and donepezil is considered safe 
and tolerable (Table 11 ).
Table 11 Operating Characteristics for a One AE Incidence Rate
Number of Subjects 
Receiving MK -1942 + 
DonepezilTrue 
RateTarget 
RateOperating Characteristics
“Go”means tolerable
“Go” if PP(AE rate ≤ Target rate )>60%
Probability of 
“Go”Probability of 
“No Go ”
18 90% 80% 10% 90%
80% 80% 51% 49%
70% 80% 83% 17%
60% 80% 97% 3%
18 70% 60% 14% 86%
60% 60% 44% 56%
50% 60% 77% 24%
40% 60% 95% 5%
CCI
087PVJ
PRODUCT: MK-1942  91
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interv entional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conduct ed 
in compliance with local and/or national regulations (including all applicable data protection regulations), and 
International Council for Harmonisation Good Clinical Practice (ICH -GCP), and also in accordance with the 
ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or com parator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants, adequac y of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by MSD personnel (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verifi ed versus 
source documentation according to standard operating procedures. Per MSD policies and procedures, if fraud, 
087PVJ
PRODUCT: MK-1942  92
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
scientific/research misconduct or serious GCP -non-compliance is suspected, the issues are investigated. 
When necessary, the clinical site will be closed, the responsible regulatory authorities and ethics review 
committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some ea rly phase or pilot trials are intended to be hypothesis -generating rather 
than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as m ultiplicity.
MSD’s policy on authorship is consistent with the recommendations published by the International Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the tria l, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regu latory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by MSD for regulatory authority 
acceptance/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by an IRB/IEC before being im plemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval.   
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of prima ry importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or individuals acting on behalf of MSD), ethics committee, and/or regulatory 
authorities wil l have access to confidential medical records that might identify the participant by name.
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics committee.
087PVJ
PRODUCT: MK-1942  93
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay inc entives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may c ompensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by MSD, and that the investiga tor or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commit ment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility to determine, based on th ese regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  the Sponsor in accord ance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to prov ide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States fo r these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
The Sponsor will conduct this study  in compliance with all applicable data protection 
regulations.
087PVJ
PRODUCT: MK-1942  94
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Participants will be assigned a unique identifier by the Sponsor. An y participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be infor med that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authori zed personnel appointed by  the S ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities.
10.1.3.1 Confidentiality of Data
By signin g this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated insti tution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2 Confidentiality of Participant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF data. By  signing the consent form, the participant agrees to this 
process. If study  documents will be photocopied during the process of verify ing 
worksheet/ CRF inform ation, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with th is study  in accordance with all applicable privacy  laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those age ncies .
10.1.4 Publication Policy
The results of this study  may  be published or presented at scientific meetings. The Sponsor 
will comply  with the requirements for publication of study  results. I n accordance with 
087PVJ
PRODUCT: MK-1942  95
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
standard editorial and ethical practice, the Sponso r will generall y support publication of 
multicenter studies only  in their entiret y and not as individual site data. I n this case, a 
coordinating investigator will be designated b y mutual agreement.
If publication activity is not directed b y the Sponsor, th e investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary  inform ation and to provide comments.
Authorship will be determined by  mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements .
10.1.5 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study  is solely  responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies f or their 
disease conditions and pursue participation b y calling a central contact number for further 
information on appropriate study  locations and study  site contact information.
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive ,or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this study  or its results to those 
registries.
10.1.6 Compliance with Law, Audit, and Debarmen t
By signing this protocol, the investigator agrees to conduct the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International C ouncil on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generall y accepted 
standards of GCP ); and all applicable federal, state and local laws, rules and regulations 
relating to the conduct of the clinical study .
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored b y MSD, is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek re imbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
087PVJ
PRODUCT: MK-1942  96
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsor’s studies. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified d esignee is responsible for verify ing that data entries are accurate and correct by  
physicall y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data docume nts.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for inspection, 
copy ing, review, and audit at reasonable times b y representatives of th e Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study agreements, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records m ay be destroy ed during 
087PVJ
PRODUCT: MK-1942  97
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or part y without written notification to the Sponsor .
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study  records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institu tionmay need to request previous medical records or transfer records, 
depending on the study . Also, current medical records must be available .
10.1.9 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor or 
designee will promptly  notify  that study  site’s IRB/IEC as specified b y applicable regulatory 
requirement(s).
087PVJ
PRODUCT: MK-1942  98
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 12will be performed by  the local laboratory .
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5of the protocol.
•Additional tests may  be performe d at any  time during the stud y as determined necessary 
by the investigator or required by  local regulations.
Table 12 Protocol -require d Safet yLaboratory  Assessments
Laboratory 
AssessmentsParameters
Hem atology Platelet Count RBC Indices:
MCV
MCH
%ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hem oglobin
Hem atocrit
Chemistry Blood Urea 
Nitrogen (BUN)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -
Oxaloacetic 
Transaminase 
(SGOT)Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
elevated above the 
upper limit of 
normal)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase 
(SGPT)Total Protein
Glucose 
[nonfasting]Calcium Alkaline 
phosphatase
Routine 
Urinalysis•Specific gravity
•pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, leukocyte 
esterase] by dipstick
•Microscopic examination (if blood or protein is abnormal)
Other Screening 
Tests•Follicle -stimulating hormone (as needed in women of nonchildbearing potential only)
•[Serum or urine] [alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opiates, cannabinoids and benzodiazepines) if applicable]
• [Serology [(HIV antibody, hepatitis B surface antigen [HBsAg], and hepatitis C virus 
antibody)]  [if applicable]
NOTES: NOTES:
•Urea is acceptable if BUN is not available as per institutional standard.
•WBC Differential: Consider if results providing the absolute or % value will be acceptable or if absolute 
values are required.
•Creatinine: GFR (measured or calculated) or creati nine clearance can be used in place of creatinine.
087PVJ
PRODUCT: MK-1942  99
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical study participant, temporally  
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or dis ease (new or exacerbated) temporally  
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, diagnost ic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run -in intervention) , manufactured by , licensed 
by, provided by , or distributed by  the Sponsor for human use in this study .
Eventsmeeting the AE definition
•Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated c linical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer.
087PVJ
PRODUCT: MK-1942  100
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
•Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
•Surgery  planned prior to informed consent to treat a pre- existing condition that has not 
worsened.
•Refe r to Section 8.4.6 for protocol -specific except ions.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
oResults in death
oIs life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
oRequires inpatient h ospitalization or prolongation of existing hospitalization
•Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a precautionary  measure for continued observation. (Note: 
Hospitalization for an e lective procedure to treat a pre -existing condition that has not 
worsened is not an SAE. )A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
oResults in persistent or significant disability/incapacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
087PVJ
PRODUCT: MK-1942  101
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
oIs a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
oOther important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may  
not be immediately  life-threatening or result in death or hospitalization but may 
jeopardize the participant or may require medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events sh ould usually  be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or deve lopment of drug dependency  
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory , and diagnostics reports ) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
087PVJ
PRODUCT: MK-1942  102
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
•There may  be instances when copies of medical records for certain cases are requested b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copies of the medical records before submission to the 
Sponsor.
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of i ntensity /toxicity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an ass essment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort, 
and not interferi ng with every day activities (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies, definitely acting like something is wrong).
-Severe: An event that prevents normal everyday  activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  used for rating the 
intensity  of an event; and both AE and SAE can be assessed as severe (for pedia tric 
studies, extremely  distressed or unable to do usual activities).
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified ph ysician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initialed 
document must be retaine d for the required regulatory  time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The followi ng components are to be used to assess the relationship between the 
Sponsor ’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the A E:
087PVJ
PRODUCT: MK-1942  103
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (pill 
count, diary , etc.), expected pharmacologic effect, or measurement of 
drug/metabolite in bod ily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? I s the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal 
product)?
-Likely Cause: Is the AE not reasonabl y explained by  another etiology  such as 
underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor ’s product discontinued or dose/exposure/frequency  
reduced?
◦If yes, did the AE resolve or improve?
◦If yes, this is a positive dechallenge.
◦If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability ; (2) the AE resolved/improved despite contin uation of the Sponsor ’s 
product; (3) the stud y is a single -dose drug stud y; or (4) Sponsor ’s product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in this study ?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability , or (2) the study  is a single -dose drug study; or (3) Sponsor ’s 
product(s) is/ are used only  1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR ’S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHAL LENGE MUST BE APPROVED I N 
ADVANCE BY THE SPONSOR CLINI CAL  DIRECTOR, AND IF REQUI RED, THE 
IRB/IEC .
087PVJ
PRODUCT: MK-1942  104
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor ’s product or drug class 
pharmacology  or toxicology ?
•The assessment of relationship will be reported on the case report forms/worksheets b y 
an investigator who is a qualified physician according to his/her best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility  of Sponso r’s product relationship:
◦There is evidence of exposure to the Sponsor ’s product. The temporal sequence 
of the AE onset relative to the administration of the Sponsor ’s product is 
reasonable. The AE is more likely  explained by  the Sponsor ’s product than by  
another cause.
-No, there is not a re asonable possibilit y of Sponsor’ s product relationship:
◦Participant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not reasonable 
OR the AE is more likely explained by  another cause than the S ponsor’s 
product. (Also entered for a participant with overdose without an associated 
AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be si tuations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initia l transmission of the SAE data to the Sponsor.
•The investigator may change his/her opinion of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality  assessment.
•The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to 
elucid ate the nature and/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
087PVJ
PRODUCT: MK-1942  105
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety e vent reporting to Sponsor via electronic 
data 
collection t ool
•The primary  mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic s ystem is unava ilable for more than 24 hours, then the site will 
use the paper AE Reporting form.
◦Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the stud y is comp leted at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by telephone (see next section).
•Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated re porting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent) .
087PVJ
PRODUCT: MK-1942  106
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definition s,Collection, and Documentation
This section is not applicable.
087PVJ
PRODUCT: MK-1942  107
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Nonchildbearing Potential (WONCBP)
Women in the following categories are considered WONCBP:
•Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpingectomy
-Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity ), inve stigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of 12 months of amenorrhea, confirmation with two 
FSH measurements in the postmenopausal range is required. 
Females on HRT and whose menopausal status is in doubt must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.
087PVJ
PRODUCT: MK-1942  108
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
•Progestogen -only subdermal contraceptive implantb,c
•Intrauterine hormone -releasing systems ( IUS)c,d
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia can come from the site personnel’s revie w of the participant’s 
medical records, medical examination, or medical history intervie w.
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse d uring the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.
a    Contraceptive use by men or w omen should be consistent with local regulations regarding the use of 
contraceptive methods for participants of clinical studies.
b    If locally required, in accordance w ith CTFG guidelines, acceptable contraceptive implants are limited to 
those which inhibit ovulation.
c    Male condoms must be used in addition to hormonal contraception .
d    IUS is a progestin releasing IUD.
Note: The follow ing are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, post-ovulation methods), w ithdrawal (coitus interruptus), 
spermicides only, and LAM.
-  Male condom with cap, diaphragm, or sponge with spermicide.
-  Male and female condom should not be used together (due to risk of failure with friction).
087PVJ
PRODUCT: MK-1942  109
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.6 Appendix 6:Collection and Management of Specimens for Future Biomedical 
Research
1.  Definitions
a. Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition .1
b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d. DNA: Deox yribonucleic acid.
e. RNA: Ribonucleic acid.
2.  Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 9will be 
used in various experiments to understand:
◦The biology  of how drugs/vaccines work
◦Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
◦Other pathway s with which drugs/vaccines may  interact
◦The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how indi
viduals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by the Sponsor or those wo rking for or 
with the Sponsor.
3.  Summary of Procedures for Future Biomedical Research.
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in 
future biomedical research.
087PVJ
PRODUCT: MK-1942  110
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study  visit by  the investigator or his or her d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present consent at next possible Participant Visit. Consent forms 
signed b y the participant will be kept at the clinical study site under secure storage for 
regul atory  reasons.
A template of each stud y site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical r esearch will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroy ed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4.  Confidential Participant Information for Fu ture Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted wi thout connecting the clinical study  data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history  and intervention outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key) between participan t 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube.
087PVJ
PRODUCT: MK-1942  111
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
5.  Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by the Sponsor, or an additional third party  (eg, a university  investigator) designated by 
the Sponsor. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in future biomedical research protocol and consent. 
Future biomedical r esearch specimens remaining with the third party  after specific
analysis is performed will be reported to the Sponsor.
6.  Withdrawal From Future Biomedical Research
Participants may  withdraw their consent for future biomedical research and ask that their 
biospecimens not be used for future biomedical r esearch. Partic ipants may withdraw 
consent at an y time b y contacting the investigator for the main study. If medical records 
for the main study  are still available, the investigator will contact the Sponsor using the 
designated mailbox (clinical.specimen.management@merck.com). Subsequently , the 
participant's specimens will be flagged in the biorepository and restricted to main study 
use only . If specimens were collected from study participants specifically for future 
biomedical r esearch, these specimens will be removed fr om the biorepository  and 
destroy ed. Documentation will be sent to the investigator confirming withdrawal and/or 
destruction, if applicable. I t is the responsibility  of the investigator to inform the 
participant of completion of the withdrawal and/or destru ction, if applicable. Any  
analyses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the s pecimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.  Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to 20 y ears from the end of the main study . Specimens may  be stored for 
longer if a regulatory  or governmental authorit y has active questions t hat are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the study  site will be shipped to a central laboratory  and then shipped to 
the Sponsor -designated bioreposit ory. If a central laboratory  is not utilized in a particular 
study , the stud y site will ship directly to the Sponsor -designated biorepository . The 
specimens will be stored under strict supervision in a limited access facility which 
087PVJ
PRODUCT: MK-1942  112
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
operates to assure the i ntegrity  of the specimens. Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database.
8.  Data Security
Databases containing specimen information and test results are accessible only  to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.  Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Pri nciple reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor m ay publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and participants. Participants will not be 
identified by  name in any published reports about th is study  or in any  other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11. Ris ks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biomedical r esearch informed consent.
The Sponsor has developed strict securit y, policies, and pro cedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly  to 
clinical.specimen.management@merck.com.
087PVJ
PRODUCT: MK-1942  113
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
13.References
1.  National Cancer Institute [I nternet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618
2.  International Council on Harmonization [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding 
Categories. Available from http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers
-pharmacogenomics -pharmacogenetics -
genomic -data-and-sample -cod.html 
3.  Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, Scope 
and Public Health Benefits of Exploratory  Biomarker Research: A Guide for I RBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/ 
4.  Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at http://i-
pwg.org/
087PVJ
PRODUCT: MK-1942  114
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.7 Appendix 7: Country -specific Requirements
This appendix is not applicable for this stud y.
087PVJ
PRODUCT: MK-1942  115
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.8 Appendix 8: Approximate Blood Volume Table
Test Pre-study Treat ment Periods Post-studyTotal 
CollectionsmL Per 
CollectionTotal 
mL/ Test
Laboratory Safety Tests 2 6 1 9 12.5 112.5
HIV/Hepatitis Screen  1 1 5 5
Blood for Planned Genetic 
Analysis 1 1 8.5 8.5
Blood for plasma MK -1942 54 54 4 216
Blood for plasma donepezil 18 18 4 72
Total Blood Volume per Participanta416.5 mL
aIf additional pharmacokinetic , pharmacodynamic and/or safety analysis is necessary, additional blood ( not to exceed 
50mL) may be obtained.
CCI
087PVJ
PRODUCT: MK-1942  116
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.9 Appendix 9: 12-Lead Electrocardiogram Abnormality Criteria
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure CriteriaPotentially Significant 
Post-randomization Findings 
(clarification on action to take)
RHYTHM
Sinus Tachycardia 110 bpmHR >110 bpm and HR increase of 
≥25bpm from baseline
Sinus Bradycardia <40 bpmHR <40 bpm and HR decrease of 
≥5bpm from baseline
Sinus Pause/Arrest >2.0 seconds >2.0 seconds
Atrial Premature C omplex 1 beat 3 beats
Ventricular Prema ture C omplex All 3 beats
Ectopic Atrial Rhythm None None
Junctional RhythmJunctional Rhythm with HR < 40 
bpmJunctional Rhythm with HR < 40 
bpm
Idioventricular Rhythm All All
Atrial Fibrillation All All
Atrial Flutter All All
Supraventricular Tachycardia All All
Ventricular Tachycardia All All
AXIS
Left Axis DeviationRBBB W ith Left Anterior 
Hem iblock (LAHB)New  Onset LAHB
Right Axis DeviationRBBB W ith Left Posterior 
Hem iblock (LPHB)New  Onset LPHB
CONDUCTION
1st Degree A V Block PR  230 msPR  230 ms   + Increase of 15 ms; 
or PR Increase of > 25%
2nd Degree AV Block Mobitz Type II Mobitz Type II
3rd Degree A V Block All All
LBBB All All
RBBBRBBB With LAHB/LPHB as 
Defined A boveNew  Onset RBBB (N ot Including 
Rate-related)
Incomplete Right BBB (ICRBBB) 
(QRS <120 ms)No E xclusion Nothing
Short PR/ Preexcitation S yndrome Delta W ave + PR <120 ms Delta W ave + PR <120 ms
Other Intra -Ventricular 
Conduction DelayQRS 130 ms QRS 130 ms + I ncrease of 10 ms
QTc (B or F)
Male QTc 470 msQTc 500 ms or I ncrease of 60 ms 
From  Baseline
Female QTc 480 msQTc 500 ms or I ncrease of 60 ms 
From  Baseline
HYPERTROPHY
Atrial Abnorm alitiesDefinite Evidence of P Mitrale or 
P Pulmo naleDefinite Evidence of P Mitrale or P
Pulmonale
087PVJ
PRODUCT: MK-1942  117
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure CriteriaPotentially Significant 
Post-randomization Findings 
(clarification on action to take)
Ventricular A bnorm alitiesVoltage Criteria for LVH P lus 
Strain PatternVoltage Criteria  for LVH P lus 
Strain Pattern
MYOCARDIAL INFARCTION
Acute or Recent All All
Old All All
ST/T MORPHOLOGY
ST Elevation S uggestive of 
Myocardial Injury In 2 or more contiguous leads In 2 or more contiguous leads
ST Depression S uggestive of
Myocardial Ischaemia In 2 or more contiguous leads In 2 or more contiguous leads
T-wave Inversions Suggestive of 
Myocardial Ischaemia In 2 or more contiguous leads In 2 or more contiguous leads
Non-specific ST -T Changes 
(In 2 or More L eads)No exclusion In 2 or more contiguous leads
PACEMAKER All All
Baseline is defined as Predose Day 1 ; ms=milliseconds, mm=millimeter
087PVJ
PRODUCT: MK-1942  118
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory  values obtained at prestud y (screening) visit and/or predose evaluation:
A.If all protocol- specified laboratory  values are normal, the participant may  enter the stud y.
B.If a protocol specified laboratory  value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study .
C.If ≥1 protocol -specified laboratory  value not specified in the inclusion/exclusion criteri a 
is outside the normal range, the following choices are available:
1. The participant may  be excluded from the study ;
2. The participant may  be included in the study  if the abnormal value(s) is NCS 
(the investigator must annotate the laboratory  value “NCS” on the laboratory  
safet y test source document).
3. The participant may  be included in the study  if the abnormalit y is consistent 
with a pre -existing medical condition which is not excluded per protocol (eg, 
elevated eosinophil count in a participant with asthma or seasonal allergies),
the medical condition should be annotated on the laboratory report .
OR
4. The abnormal test may  be repeated (refer items a. and b. below for 
continuation of algorithm for repeated values).
If the repeat test value is within the normal range, the participant may  enter the study .
If the repeat test value is still abnormal, the study investigator will evaluate the potential 
participant with a complete history  and ph ysical examination, looking especially  for 
diseases that could result in the abnormal laboratory value in question. If such diseases 
can be ruled out, and if the abnormal laboratory  value is not clinically  relevant, then the 
participant may  enter the study .
D.If there is an y clinical uncertaint y regarding the significance of a n abnormal value, the 
participant will be excluded from the stud y
087PVJ
PRODUCT: MK-1942  119
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.11 Appendix 11: The General and Targeted Neurological Exams
The General and Targeted Neurological Examination will be performed at the time points 
specified in the Schedule of Activities (Sec tion 1.3).
Note to the investigator : If at any time abnormalities are observed in the General or 
Targeted Neurological Exams, the Investigator should do additional examinations as 
needed based on his or her medical judgment.
The General Neurological Examin ation
The General Neurological Examination includes all of the modules listed below and is 
intended to be a general screening examination.
MODULE 1 – MENTAL STATUS EXAMINATION
A. General Level of Arousal (generally assess general level of alertness, attent iveness, and 
concentration throughout the interview. Regarding attentiveness, note evidence of 
impaired attention or concentration. For example difficulty  remembering or following 
instructions or distractibility  may  be signs of inattention)
B. Thought Proc esses and L anguage (generall y assess logic, relevance, organization and 
coherence of volunteer’s use of language throughout the interview).
C. Orientation (time, place, person).
D.Attention/Concentration
Ask the participant to count backwards from 100 by  7’s (“Serial 7’s”) or ask to recite months 
backwards or spell a 5 unique letter word (eg “WORL D”) backwards.
Note: To avoid learning effects, switch between tests throughout the stud y
E. Memory  (test registration of 3 objects; then test immediate recall 5 minutes later).
Grade: NORMAL or IMPAIRED anddescribe abnormality (for each, A 
to E, above). Normal performance on Serial 7’s is getting to 65 with no 
more than one error.
087PVJ
PRODUCT: MK-1942  120
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
MODULE 2 – CRANIAL NERVE ASSESSMENT
A. II–Eyesight 
B. II, III–Pupil Size and Reactivity
C. III, IV, VI – Extraocular Movements (range of motion, smooth pursuit, saccades, 
nystagmus).
1. Observe for n ystagmus during ey e movements, increased ny stagmus at the 
end of gaze or other oculomotor changes (mild n ystagmus at e xtremes of gaze 
is normal). Note direction of nystagmus
D. V – Facial Sensation, Jaw Strength
E. VII –Muscles of Facial Expression (wrinkle brow, squeeze ey es shut, smile)
F. VIII–Auditory  Acuity  (assessed using a bed -side screening test eg by  rubbing f ingers on 
each side of participant ’s head or b y whispering numbers)
G. IX– Gag reflex
H. X – Swallow
I. XI–Shoulder shrug
J. Tongue Protrusion (midline)
Score: left and right (except for G, H, J)
Grade: NORMAL or IMPAIRED and describe abnormality
MODULE 3 -MOTOR SYSTEM
A. Muscle Tone
1. Ask the volunteer to relax.
2. Flex and extend the volunteer’s elbows and knees (bilaterall y).
3. There is a small, continuous resistance to passive movement.
4. Observe for involuntary movements (eg, tremor, tics, fasciculations). Observe for 
resistance to passive movement; observe for decreased (flaccid) or increased 
(rigid/spastic) tone.
Score : left and right
Grade :NORMAL, INCREASED or DECREASED
087PVJ
PRODUCT: MK-1942  121
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
B. Muscle Strength
1. Ask the participant to stand up from sitting without using hands
Grade : NORMAL, IMPAIRED and describe abnormality
2. Test proximal limb strength b y having the volunteer flex and extend the knees and 
elbows against your resistance.
Test bilaterall y and compare one side to the other.
Score : left and ri ght
Grade: 5/5: normal; 
4/5: movement against resistance impaired; 
3/5: movement against gravity but not against resistance; 
2/5: visible movement but not against gravity; 
1/5: visible contraction; 
0/5: no visible activity
3. Test distal limb strength by having the volunteer conduct dorsiflexion and plantar 
flexion of the volunteer’s feet; finger abduction and handgrip strength against your 
resistance.
Test bilaterall y and compare one side to the other.
Score : left and right
Grade : 5/5: normal; 
4/5: movement against resistance impaired; 
3/5: movement against gravity but not against resistance; 
2/5: visible movement but not against gravity; 
1/5: visible contraction; 
0/5: no visible activity
087PVJ
PRODUCT: MK-1942  122
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
C. Pronator Drift
1. Ask the volunteer to hold both arms straight forward with, palms up and eyes 
closed for ≈10 -15 seconds as tolerated; watch for how well the arm position is 
maintained.
2. Instruct the volunteer to keep both arms still while y ou tap them briskl y downward.
The volunteer should normally  be able to maintain extension and supination. I nability  
to maintain extension and supination (and drift into pronation) indicates an upper 
motor neuron deficit.
Score : left and right
Grade : NORMAL or IMPAIRED and describe abnormality
MODULE 4 - REFLEXES
A. Biceps
B. Knee
Note : Other deep tendon reflexes may be tested at Investigator's discretion (eg 
elbow, wrist or Achilles tendon)
Score : left and right
Grade : NORMAL, INCREASED, DECREASED or ABSENT
C. Babinski
Score : left and right
Grade : NORMAL or ABNORMAL
MODULE 5 - COORDINATION AND GAIT
A. Rapid, Rhy thmic Alternating Movements
1. Testing each hand separately, ask the volunteer to tap the distal thumb with the tip 
of each finger, in sequence, as fast as possible.
Score : left and right
Grade : NORMAL or IMPAI RED
Reminder : If the rapid alternate movements are disturbed, the participant will 
be asked to strike his hand on the thigh, raise the hand, turn it over and then 
strike the back of the hand down on the same place. (This test is impaired in 
cerebellar dise ase, extra py ramidal disease and upper MN weakness.)
087PVJ
PRODUCT: MK-1942  123
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
B. Point- to-Point Movements
1. Ask the volunteer to touch y our index finger and their nose alternatel y several 
times. Move y our finger about as the volunteer performs this task.
Score : left and right
Grade : NORMAL or IMPAIRED
Reminder : If the point -to-point testing is disturbed, the participant will be 
asked to place one heel on the opposite knee and then run it down the shin to 
the big toe. Repeat this for both sides. (Impaired tests indicate cerebellar 
disease.)
C. Romberg
1. Ask the volunteer to stand with both feet together and eyes closed for 20 to 30 
seconds without support.
2. Be prepared to catch the volunteer if they are unstable.
Grade : NORMAL or IMPAIRED
D. Gait
1. Ask the volunteer to walk across the room, turn and come back (assess posture, 
balance, swinging of arms and movement of the legs).
Grade : NORMAL or IMPAIRED and describe abnormality
2. Ask the volunteer to walk heel -to-toe in a straight line (tandem gait).
Grade : NORMAL or IMPAIRE D and describe abnormality
MODULE 6 - SENSORY
A. Light touch sense: cotton wisp on skin of forearms and legs, bilaterall y.
B. Pin prick: safety  pin touched lightl y to skin of forearms and legs, bilaterally.
C. Vibration: tuning fork vibration detection in hands, feet bilaterally .
D. Stereognosis: (identify common objects placed in hand, eg, coin, key).
Score : left and right
Grade : NORMAL OR IMPAIRED and describe abnormality (for each A 
to F)
087PVJ
PRODUCT: MK-1942  124
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
The Targeted Neurological Examination
The Targeted Neurological Examination, which is intended to focus on tests where drug 
effects can be seen, includes the following tests only:
MODULE 1 – MENTAL STATUS EXAMINATION
A. General Level of Arousal (generally assess general level of alertness, attentiveness, and 
concentrat ion throughout the interview. Regarding attentiveness, note evidence of impaired 
attention or concentration. For example difficult y remembering or following instructions or 
distractibility  may  be signs of inattention)
MODULE 2 – CRANIAL NERVE ASSESSMENT
B.II, III –Pupil Size and Reactivity
C. III, IV, VI – Extraocular Movements (range of motion, smooth pursuit, saccades, 
nystagmus
1. Observe for n ystagmus during ey e movements, increased ny stagmus at the end of 
gaze or other oculomotor changes (mild n ystagmus at extremes of gaze is normal). 
Note direction of n ystagmus
MODULE 3 - MOTOR SYSTEM
B. Muscle Strength
1. Ask the participant to stand up from sitting without using hands
Grade : NORMAL, IMPAIRED and describe abnormality
MODULE 5 - GAIT
B. Gait
1. Ask t he volunteer to walk across the room, turn and come back (assess posture, 
balance, swinging of arms and movement of the legs).
Grade : NORMAL or IMPAIRED and describe abnormality
2. Ask the volunteer to walk heel -to-toe in a straight line (tandem gait).
Grade : NORMAL or IMPAIRED and describe abnormality
087PVJ
PRODUCT: MK-1942  125
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.12 Appendix 12: Additional Information to be Collected from Subjects Who Report 
Suicidal Ideation and/or Behavior
Adverse events of suicidal ideation and/or behavior must be reported to Merck as an Event of
Clinical I nterest (ECI) within 24 hours of observation. Suicidal ideation and behavior may  be 
identified through spontaneous participant reports and/or upon review of the C -SSRS 
responses or other assessment tools.
Participants who at an y time during this study  spontaneously  report AEs of suicidal ideation 
or behavior, either as an outpatient or during visit interviews, or whose responses to the 
QIDS-SR16 (when assessed) or C -SSRS are suggestive of suicidal ideation and behavior, 
must be assessed b y the in vestigator and referred for further mental health evaluation. 
Participants with treatment -emergent suicidal ideation and/ or behavior must be evaluated 
that day  by a psychiatrist or other trained mental health professional who is a licensed 
psychologist, s ocial worker or nurse practitioner (or comparable professional qualification in 
countries outside the United States). Only  patients whose suicidal ideation is passive, who 
expressly  deny any intent to act, and who, after evaluation, are not judged to be at serious 
risk for self -harm during the course of the study  may  continue in the study ; others must be 
discontinued from study  participation and receive appropriate clinical follow -up care to 
assure their safet y.
The investigator will collect the following i nformation, in addition to any  other relevant 
information deemed appropriate b y the investigator or Sponsor. It is important to also note 
pertinent negatives where applicable to convey  that the information was collected. This 
information must be entered in INFORM in narrative format in the Adverse Experience free 
text fields. These data will be used to provide a narrative summary of the event.
087PVJ
PRODUCT: MK-1942  126
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
10.13 Appendix 13: Abbreviations
Abbreviation Expanded Term
AChEI acetylcholinesterase inhibitor
AD Alzheimer’s disease
AE adverse event 
ALT Alanine aminotransferase
AMP A α-amino -3-hydroxy -5-methyl -4-isoxazolepropionic acid
APaT All-Participants -as-Treated
AST Aspartate aminotransferase
ATD accelerated titration design
AUC area under the plasma concentration -time curve
β-hCG β-human chorionic gonadotropin
BID twice daily
BMI body mass index
BP blood pressure
BT body temperature
CI confidence interval
CG Cockcroft -Gault
CNS central nervous system 
CKD -EPI Chronic Kidney Dise ase Epidemiology Collaboration
CL clearance
Cmax maximum plasma concentration
CrCl creatinine clearance
CRF case report form 
CRU clinical research unit
C-SSRS Columbia -Suicide Severity Rating Scale 
C-SSRS/SLA C-SSRS since last assessment
CSR clinical study report
CTCAE Common Term inology Criteria for Adverse Events
CTCAE 4.0 Common Terminology Criteria f or Adverse Events, Version 4.0
Ctrough trough plasma concentration
D day
DBP diastolic blood pressure
DFC dry filled capsule
DILI drug-induced liver injury
DNA deoxyribonucleic acid 
DSM -5 Diagnostic and Statistical Manual of Mental Disorders, 5thedition
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic case report form
EDC electronic data collection 
eGFR estimated glomerular filtratio n rate
ELISA enzyme-linked immunosorbent assay
EMA European Medicines Agency
F fluoride
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
FSH follicle stimulating hormone 
GCP good clinical practice 
GI gastrointestinal
HBsAg hepatitis B surface antigen
CCI
087PVJ
PRODUCT: MK-1942  127
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
Abbreviation Expanded Term
HBV hepatit is B virus
HCl hydrochloride
HEV healthy elderly volunteer
HIV human immunodeficiency virus
hr hour
HR heart rate
IB Investigator’s Brochure 
ID/pbo investigational drug/placebo
ICF informed consent form
ICH International C ouncil on Harmonization
IEC Institutional Ethics Committee
IMP/NIMP Investigational/Non -Investigational Medicinal Product
IND Investigational New Drug 
IRB Institutional Review Board
IUD intrauterine device
IV intravenous
MedDRA Medical Dictionary for Regulatory Activities
mg milligram
NCS not clinically significant
NDA New  Drug Application 
nH Hill coefficient
NOAEL no observed adverse effect level 
Occ50 compound concentration resulting in 50% occupancy of a receptor
OSF on-site formulation
PD pharmacodynamic
PI principal investigator
PK pharmacokinetic
PO orally
PP per-protocol
QD Quaque die (d aily)
QTc corrected QT interval
RNA ribonucleic acid
RO receptor occupancy
RR respiratory rate
SAE serious adverse event 
SAP statistical analysis plan
SBP systolic blood pressure
SoA schedule of activities
SUSAR suspected unexpected serious adverse reaction
t1/2 half-life
tmax time to maximum plasma concentration
UDS urine drug screen
V volume of distribution
VS vital sign
WAIS Wechsler adult intelligence scale
WBC white blood cell
WONCBP woman/ women of non-childbearing potential 
CCI
087PVJ
PRODUCT: MK-1942  128
PROTOCOL/AMENDMENT N O.:005-01 
MK-1942 -005-01FINAL PROTOCOL 16-MAR -2020
11 REFERENCES
[O'Keeffe, S. T., et al 
1996]O'Keeffe ST, Kazeem H, Philpott RM, Play fer 
JR, Gosney  M, Lye M. Gait disturbance in 
Alzheimer's disease: a clinical study . Age 
Ageing. 1996;25:313- 6.05DHHF
[Jackson, S., et al 2004] Jackson S, Ham RJ, Wilkinson D. The safet y and 
tolerability  of donepezil in patients with 
Alzheimer's disease. Br J Clin Pharmacol. 
2004;58(S1):1- 8.05DHHD
087PVJ